Respiratory syncytial virus vaccine as well as preparation method therefor and use thereof

By designing an immune composition containing the pre-fusion F protein antigen of human respiratory syncytial virus, combined with lipid nanoparticle delivery technology, the problems of antigen stability and immune response in RSV vaccines were solved, and efficient neutralizing antibody induction and cell induction were achieved Immune response.

WO2024239890A1PCT designated stage expired Publication Date: 2024-11-28LIVERNA THERAPEUTICS INC
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/089467
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-04-24
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing RSV vaccines are difficult to induce high titer neutralizing antibodies, especially for the modification of the stability of F protein before fusion, which affects the development and application of vaccines.

Method used

Provide an immune composition containing the pre-fusion F protein antigen of human respiratory syncytial virus, using specific amino acid sequence variants and multimerization elements designed through nucleic acid or polypeptide form, and combining lipid nanoparticle delivery technology to improve the stability of the antigen. sexual and immune responses.

Benefits of technology

The RSV neutralizing antibody titer and IgG antibody titer in mouse serum were significantly improved, induced a strong cellular immune response, and provided effective protection against RSV.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024089467_28112024_PF_FP_ABST
    Figure CN2024089467_28112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is an immune composition, the immune composition comprising or encoding a human respiratory syncytial virus antigen, and the immune composition being selected from a nucleic acid immune composition, a polypeptide immune composition or a virus immune composition.
Need to check novelty before this filing date? Find Prior Art

Description

Respiratory syncytial virus vaccine and its preparation method and application

[0001] This application claims priority to a Chinese patent application filed on May 19, 2023 (application number: 202310570847.2, invention name: Respiratory syncytial virus vaccine, preparation method and application thereof). The entire contents of the Chinese patent application are incorporated herein by reference in their entirety. Technical Field

[0002] The present disclosure relates to the field of gene medicine technology, and in particular to a respiratory syncytial virus vaccine and a preparation method and application thereof. Background Art

[0003] The statements herein merely provide background information related to the present disclosure and may not necessarily constitute prior art.

[0004] Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in infants and young children, severely impacting their health. RSV infection does not provide lasting immunity, leading to frequent reinfection. RSV infection is a global public health concern, with local outbreaks potentially occurring. However, there is currently no approved RSV vaccine.

[0005] The RSV genome is approximately 15–16 kb in size and encodes 11 proteins, including eight structural proteins and three nonstructural proteins (NS1, NS2, and M2-2). The structural proteins include three transmembrane surface proteins (G, F, and SH), two matrix proteins (M and M2-1), and three nucleocapsid proteins (L, N, and P). The G protein mediates viral binding to host cells, while the F protein mediates fusion of the virus and host cell membranes, enabling viral entry. Both proteins are crucial for viral replication and contain B and T cell epitopes, making them the most important viral antigens for stimulating humoral and cellular immunity. The G protein coding region exhibits significant variation, resulting in subtypes A and B, and the neutralizing antibodies induced by the G protein are subtype-specific. The F protein coding region is highly conserved, with the amino acid sequences of the F proteins of subtypes A and B being at least 90% identical. Therefore, neutralizing antibodies induced by the F protein can inhibit infection with both subtypes A and B. The structure of the F protein changes dynamically. It is first transcribed and translated into a single inactive polypeptide (F0) in the host cell. It is then cleaved for the first time by the host cell furin protease to generate a partially cleaved prefusogenic protein. This is followed by a second furin cleavage to generate F2 and F1 subunits. The two subunits are linked to a monomer by two disulfide covalent bonds. The three monomers then form a metastable functional prefusion protein trimer. After this, it can undergo conformational rearrangement without further processing to form a thermodynamically stable postfusion F protein. The timing and cellular location of the two furin cleavages and conformational rearrangements are not yet fully understood, nor are the conditions that induce conformational rearrangements. The antigenic epitopes on the surface of the F protein that are associated with neutralization activity are mainly I, II, III, IV, V, and Species, of which epitopes I, II, III, and IV are present in the F protein before and after fusion; V and It is a specific antigenic site of the F protein before fusion. The F protein after fusion does not have these two epitopes. Epidemiological studies have shown that RSV neutralizing antibodies can prevent severe RSV-ALRI. The neutralizing activity of monoclonal antibodies is 10 to 100 times that of monoclonal antibodies targeting epitope II, and the neutralizing activity of monoclonal antibodies targeting epitope VIII is also very high. Therefore, most RSV neutralizing activity in serum is only directed against the prefusion F protein antigenic site. The inventors recognized that inducing high titers of neutralizing antibodies is the main goal of RSV vaccine development, and the prefusion F protein with specific antigenic epitopes has become the most popular RSV vaccine target. However, the prefusion F protein is inherently unstable, and making various stability modifications to it without losing important antigenic epitopes is one of the difficulties in RSV vaccine development.

[0006] Summary of the Invention

[0007] In some embodiments, the present disclosure provides an immune composition comprising or encoding a human respiratory syncytial virus (hRSV) antigen, which can elicit an effective neutralizing antibody response against human respiratory syncytial virus (hRSV).

[0008] Some aspects of the present disclosure provide an immune composition comprising or encoding a human respiratory syncytial virus (hRSV) antigen, wherein the immune composition is selected from a nucleic acid immune composition, a polypeptide immune composition, or a viral immune composition.

[0009] In some embodiments, the antigen is a prefusion hRSV F protein, and the amino acid sequence of the prefusion hRSV F protein includes a TM sequence and a multimerization element.

[0010] In some embodiments, the amino acid sequence of the multimerization element is shown as Seq ID NO.1-12, Seq ID NO.14-15.

[0011] In some embodiments, the amino acid sequence of the multimerization element is shown as one of Seq ID NO.7 and Seq ID NO.12.

[0012] In some embodiments, the P27 sequence of the pre-fusion hRSV F protein variant is substituted with a GS sequence.

[0013] In some embodiments, the GS sequence comprises (GnS)m, (GGGGS)o, GGSGGGGSGG, GGSGGGGG, GSGSGSGS, (Gly)p, (EAAAK)q, such as Seq ID NO.48~61, Seq ID NO.74 (wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; o is an integer from 1 to 5; p is an integer from 1 to 40; q is an integer from 1 to 5).

[0014] In some embodiments, the amino acid sequence of the GS sequence is shown in Seq ID NO.74.

[0015] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein variant includes at least one of an S46G substitution, an N67I substitution, an E92D substitution, a P102A substitution, an A149C substitution, an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, an L373R substitution, an S215P substitution, an I379V substitution, an M447V substitution, a Y458C substitution, a K465Q substitution, a D486C substitution, and a D489C substitution.

[0016] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L ​​substitution, and an S290C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is substituted with a GS sequence.

[0017] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L ​​substitution, and an S290C substitution; the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence as shown in Seq ID NO.74; and the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12.

[0018] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L ​​substitution, and an S290C substitution; the P27 sequence of the pre-fusion hRSV F protein is replaced with the GS sequence shown in Seq ID NO.74; the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the pre-fusion hRSV F protein further includes at least one of an S46G substitution, an N67I substitution, an E92D substitution, a P102A substitution, an A149C substitution, an L373R substitution, an S215P substitution, an I379V substitution, an M447V substitution, a Y458C substitution, a K465Q substitution, a D486C substitution, and a D489C substitution.

[0019] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, a D486C substitution, and a D489C substitution.

[0020] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, a D486C substitution, and a D489C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is substituted with a GS sequence.

[0021] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, a D486C substitution, a D489C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence as shown in Seq ID NO. 74, and / or the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO. 7 and Seq ID NO. 12.

[0022] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, a D486C substitution, and a D489C substitution, and the P27 sequence of the pre-fusion hRSV F protein is replaced with the GS sequence shown in Seq ID NO.74, and the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the pre-fusion hRSV F protein further includes at least one of an S46G substitution, an N67I substitution, an E92D substitution, a P102A substitution, an A149C substitution, an L373R substitution, an S215P substitution, an I379V substitution, an M447V substitution, a Y458C substitution, and a K465Q substitution.

[0023] In some embodiments, the pre-fusion hRSV F protein variant includes an amino acid sequence in which at least one amino acid of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence, or the 551-574 sequence is deleted consecutively or intermittently.

[0024] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein is shown as Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.68, Seq ID NO.70, Seq ID NO.72, Seq ID NO.76, and Seq ID NO.78.

[0025] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein is shown as Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, or Seq ID NO.78.

[0026] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein is shown as Seq ID NO.62, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, or Seq ID NO.78.

[0027] In some embodiments, the multimerization element of the pre-fusion hRSV F protein can also be selected from the amino acid sequences shown in Seq ID NOs. 1-12 and Seq ID NOs. 14-15.

[0028] In some embodiments, the immune composition is a nucleic acid immune composition.

[0029] In some embodiments, the nucleic acid immune composition comprises a nucleic acid molecule.

[0030] In some embodiments, the nucleic acid molecule comprises a DNA molecule and / or an RNA molecule.

[0031] In some embodiments, the DNA molecules include linear DNA molecules and / or circular DNA molecules.

[0032] In some embodiments, the RNA molecule comprises mRNA or circular RNA.

[0033] In some embodiments, the mRNA molecule includes an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown as Seq ID NO.63, Seq ID NO.65, Seq ID NO.67, Seq ID NO.69, Seq ID NO.71, Seq ID NO.73, Seq ID NO.77, Seq ID NO.79, and Seq ID NOs.84 to 103.

[0034] In some embodiments, the mRNA molecule includes an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown as Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, and Seq ID NOs.84-103.

[0035] In some embodiments, the mRNA molecule includes an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown as Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, and Seq ID NO.92-103.

[0036] In some embodiments, the mRNA molecule includes an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown as Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103.

[0037] In some embodiments, the mRNA molecule includes an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.67.

[0038] In some embodiments, the mRNA molecule includes an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.71.

[0039] In some embodiments, the nucleotide sequence of the multimerization element in the open reading frame (ORF) can also be as shown in Seq ID NO.36-47, Seq ID NO.13.

[0040] In some embodiments, the immunological composition comprises a delivery formulation; in some embodiments, the delivery formulation comprises lipid nanoparticles or cationic liposomes.

[0041] In some embodiments, the mRNA and a delivery formulation are mixed to form an immunological composition; the delivery formulation comprises lipid nanoparticles or cationic liposomes.

[0042] In some embodiments, the present disclosure provides an isolated mRNA, wherein the coding region nucleic acid sequence of the mRNA encodes a pre-fusion hRSV F protein, and the amino acid sequence of the pre-fusion hRSV F protein includes a TM sequence and a multimerization element; preferably, the amino acid sequence of the multimerization element is as shown in Seq ID NO.1-12, Seq ID NO.14-15; preferably, the amino acid sequence of the multimerization element is as shown in one of Seq ID NO.7 and Seq ID NO.12.

[0043] In some embodiments, the mRNA further comprises at least one of a 5' end cap, a 5' UTR, a 3' UTR, and a 3' end poly A tail.

[0044] In some embodiments, the 5' end cap is selected from ARCA, mCAP, dmCAP, tmCAP, m7G(5"")ppp(5"")(2""OMeA)pG, m7(3""OMeG)(5"")ppp(5"")(2""OMeA)pG, m7(3""OMeG)(5"")ppp(5"")(2""OMeG)pG, dmCAP or m7G(5"")ppp(5"")(2""OMeG)pG;

[0045] In some embodiments, the 5' end cap is m7Gppp(5')(2'-OMeA)pG.

[0046] In some embodiments, the 3'-end polyA tail is 50 to 200 nt in length.

[0047] In some embodiments, the 3'-end polyA tail is 80-200 nt in length.

[0048] In some embodiments, the 3' poly A tail has a length of 80 to 120. In some embodiments, the 3' poly A tail has a length of 120.

[0049] In some embodiments, the length of the 5'UTR is preferably 10 to 200 nucleotides.

[0050] In some embodiments, the 5'UTR is 15 to 100 nucleotides in length.

[0051] In some embodiments, the 5'UTR nucleotide sequence is as shown in Seq ID NOs. 16-18.

[0052] In some embodiments, the 5'UTR nucleotide sequence is as shown in Seq ID NO.16.

[0053] In some embodiments, the 3'UTR sequence is as shown in Seq ID NOs. 19-21.

[0054] In some embodiments, the 3'UTR sequence is as shown in Seq ID NO.19.

[0055] In some embodiments, one or more uridines in the mRNA are replaced with modified nucleosides.

[0056] In some embodiments, the modified nucleoside is pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ), or 5-methyl-uridine (m5U) (m5U).

[0057] In some embodiments, the modified nucleoside is N1-methyl-pseudouridine (m1ψ).

[0058] In some embodiments, the present disclosure provides an isolated DNA, wherein the DNA is obtained by reverse transcription of the isolated mRNA nucleic acid, or the DNA is a sequence capable of transcribing the isolated mRNA.

[0059] In some embodiments, the present disclosure provides a biological material, comprising any one of an expression cassette, a vector, an engineered bacterium, or a cell line, wherein the biological material contains or expresses the isolated mRNA or the isolated DNA. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] In order to more clearly illustrate the specific embodiments of the present disclosure or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the specific embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present disclosure. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0061] FIG1 shows a schematic diagram of the wild-type hRSV F protein.

[0062] FIG2 shows a schematic diagram of hRSV F protein variants.

[0063] Figure 3 shows a schematic diagram of the mouse experiment evaluation process.

[0064] FIG4 shows the flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells in Example 5.

[0065] FIG5 shows the ELISA detection of IFN-γ and L4 in the cell culture supernatant in Example 5.

[0066] FIG6 shows the RSV neutralizing antibody titer in mouse serum in Example 5.

[0067] FIG7 shows a statistical graph of RSV-F protein-specific IgG antibody titers in mouse serum detected by ELISA in Example 6.

[0068] FIG8 shows the flow cytometric detection of TNFα+CD4+ and TNF-α+CD8+ T cells in Example 6.

[0069] FIG9 shows the ELISA detection of IFN-γ and IL2 in the cell culture supernatant in Example 6.

[0070] FIG10 shows the ELISA detection of IL4 and IL10 in the cell culture supernatant in Example 6.

[0071] FIG. 11 shows RSV neutralizing antibody titers in mouse sera in Example 6.

[0072] FIG12 shows the flow cytometric detection of TNFα+CD4+ and TNF-α+CD8+ T cells in Example 7.

[0073] FIG13 shows the flow cytometric detection of IFN-γ+CD4+ and IFN-γ+CD8+ T cells in Example 7.

[0074] FIG14 shows the ELISA detection of IFN-γ and IL2 in the cell culture supernatant in Example 7.

[0075] FIG15 shows the ELISA detection of IL4 and IL10 in the cell culture supernatant in Example 7.

[0076] FIG. 16 shows RSV neutralizing antibody titers in mouse sera in Example 7. FIG.

[0077] FIG17 shows the flow cytometric detection of TNFα+CD4+ and TNF-α+CD8+ T cells in Example 8.

[0078] FIG18 shows the flow cytometric detection of IFN-γ+CD4+ and IFN-γ+CD8+ T cells in Example 8.

[0079] FIG19 shows the ELISA detection of IFN-γ and IL2 in the cell culture supernatant in Example 8.

[0080] FIG20 shows the detection of IL4 and IL10 in the cell culture supernatant by ELISA in Example 8.

[0081] FIG. 21 shows RSV neutralizing antibody titers in mouse sera in Example 8.

[0082] FIG. 22 shows RSV neutralizing antibody titers in mouse sera in Example 9.

[0083] FIG. 23 shows RSV neutralizing antibody titers in mouse sera in Example 11.

[0084] FIG. 24 shows RSV neutralizing antibody titers in mouse sera in Example 12.

[0085] FIG. 25 shows RSV neutralizing antibody titers in mouse sera in Example 12.

[0086] FIG. 26 shows RSV neutralizing antibody titers in mouse sera in Example 12.

[0087] FIG27 shows a graph showing the weight change trend of mice in Example 13.

[0088] FIG28 shows a trend chart of the weight change rate of mice in Example 13.

[0089] FIG29 shows a statistical graph of RSV-F protein-specific IgG antibody titers in mouse serum detected by ELISA in Example 13.

[0090] FIG30 shows the results of the RSV-A / B strain neutralizing antibody titer detection in mouse serum in Example 13.

[0091] FIG31 shows the results of virus titer detection in lung tissue of mice after RSV infection in Example 13.

[0092] FIG32 shows the results of lung tissue pathology of mice infected with RSV in Example 13. DETAILED DESCRIPTION

[0093] FIG1 shows a schematic diagram of a wild-type prefusion hRSV F protein; FIG2 shows a schematic diagram of one of the prefusion hRSV F proteins (prefusion hRSV F protein variants) of the immune composition antigens described in the present disclosure.

[0094] ↓ is furin cleavage; SP is the signal peptide sequence; P27 is the 27aa peptide sequence removed after cleavage; RR1 is repeat folding region 1, spanning 137 to 216 amino acid residues of the wild type of pre-fusion hRSVF protein, including the fusion peptide and the heptad repeat sequence A (HRA); RR2 is repeat folding region 2, which forms the C-terminal stem in the pre-fusion hRSVF protein spike, including the heptad repeat sequence B (HRB) relocated to the other side of the pre-fusion RSVF protein head; the 525-529 sequence is a sequence connecting RR2 and TM; TM is the transmembrane region sequence; the 551-574 sequence is a sequence attached to the C-terminus of the TM sequence.

[0095] F2 usually contains amino acid residues 26 to 109 of the F0 precursor; F1 usually contains amino acid residues 137 to 574 of the F0 precursor; F1 and F2 are linked by disulfide bonds to form a heterodimer, which is called the RSVF "protomer".

[0096] In this disclosure, "pre-fusion hRSV F protein wild type" or "pre-fusion hRSV F protein (wild type)" refers to the wild type pre-fusion hRSV F protein that has not been artificially modified or mutated.

[0097] The C-terminus shown in Figure 2 may be deleted or selected from at least one of the TM sequence, the 525-529 sequence, the 551-574 sequence, and the multimerization element. In some embodiments, the C-terminus of the pre-fusion hRSV F protein variant described herein is deleted. In some embodiments, the C-terminus of the pre-fusion hRSV F protein variant is a TM sequence. In some embodiments, the C-terminus of the pre-fusion hRSV F protein variant is a TM sequence and a multimerization element, sequentially linked together, wherein the C-terminus of the TM sequence is linked to the N-terminus of the multimerization element. In some embodiments, the C-terminus of the pre-fusion hRSV F protein variant is a TM sequence. In some embodiments, the C-terminus of the pre-fusion hRSV F protein variant is a TM sequence, a 551-574 sequence, and a multimerization element, sequentially linked together, wherein the C-terminus of the TM sequence is linked to the 551-574 sequence, and the C-terminus of the 551-574 sequence is linked to the N-terminus of the multimerization element. In some embodiments, the C-terminus of the pre-fusion hRSV F protein variant is a multimerization element.

[0098] The multimerization elements described in the present disclosure include dimerization elements, trimerization elements, tetramerization elements, and oligomerization elements, which, when used in combination with the hRSV F protein of the present disclosure, can result in the formation of a multimeric hRSV F protein complex; the multimerization element can be located at the N-terminus or C-terminus of the hRSV F protein, and its coding sequence is generally placed in a 5' or 3' frame to the coding sequence at the nucleic acid level.

[0099] In some embodiments, the dimerization element can be selected from, for example, a dimerization element / domain of a heat shock protein, an immunoglobulin Fc domain, and a leucine zipper (a dimerization domain of a basic region leucine zipper transcription factor), for specific amino acid sequences, see, for example, Seq ID NOs. 1-2. The trimerization and tetramerization elements can be selected from, for example, an engineered leucine zipper (an engineered helix-helix coiled peptide that adopts a parallel trimer state), the fibrin fold domain of Enterobacteriaceae phage T4, GCN4PLL, CCN4-PLI, p53, GCN4, for specific amino acid sequences, see Seq ID NOs. 3-12 (trimerization) and Seq ID NOs. 14-15 (tetramerization).

[0100] The pre-fusion hRSV F protein variants described in the present disclosure are artificially mutated and modified F proteins, and the mutations and modifications (including but not limited to amino acid residue substitutions, amino acid residue insertions and / or additions, amino acid residue deletions and covalent modifications to the amino acid sequence) are obtained by mutation and modification of the pre-fusion hRSV F protein wild type to obtain an amino acid sequence that conforms to the pre-fusion hRSV F protein. In some embodiments of the present disclosure, "pre-fusion hRSV F protein" is not described as "pre-fusion hRSV F protein wild type" or "pre-fusion hRSV F protein (wild type)", then "pre-fusion hRSV F protein" is a pre-fusion hRSV F protein variant.

[0101] In some embodiments, the GS sequence comprises, for example, (GnS)m, (GGGGS), GGSGGGGSGG, GGSGGGGG, GSGSGSGS, (Gly)p, (EAAAK)q, as shown in Seq ID NOs. 48-61, and Seq ID NO. 74 (wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20; m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20; o is an integer from 1 to 5; p is an integer from 1 to 40; and q is an integer from 1 to 5). Furthermore, in some embodiments, the amino acid sequence of the GS sequence is as shown in Seq ID NO. 74, or the nucleotide sequence encoding the amino acid sequence after sequence optimization is as shown in Seq ID NO. 74.

[0102] In some embodiments, the present disclosure provides an immune composition comprising or encoding a human respiratory syncytial virus (hRSV) antigen, wherein the antigen can elicit an effective neutralizing antibody response against human respiratory syncytial virus (hRSV).

[0103] Some aspects of the present disclosure provide an immune composition comprising or encoding a human respiratory syncytial virus (hRSV) antigen, wherein the immune composition is selected from a nucleic acid immune composition, a polypeptide immune composition, or a viral immune composition.

[0104] In some embodiments, the antigen is a prefusion hRSV F protein, and the amino acid sequence of the prefusion hRSV F protein includes a TM sequence and a multimerization element.

[0105] In some embodiments, the amino acid sequence of the multimerization element is shown as Seq ID NO.1-12 and Seq ID NO.14-15.

[0106] In some embodiments, the amino acid sequence of the multimerization element is shown as one of Seq ID NO.7 and Seq ID NO.12.

[0107] In some embodiments, the P27 sequence of the pre-fusion hRSV F protein variant is substituted with a GS sequence.

[0108] In some embodiments, the GS sequence comprises (GnS)m, (GGGGS)o, GGSGGGGSGG, GGSGGGGG, GSGSGSGS, (Gly)p, (EAAAK)q, such as Seq ID NO.48~61, Seq ID NO.74 (wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; o is an integer from 1 to 5; p is an integer from 1 to 40; q is an integer from 1 to 5).

[0109] In some embodiments, the amino acid sequence of the GS sequence is shown in Seq ID NO.74.

[0110] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein variant includes at least one of an S46G substitution, an N67I substitution, an E92D substitution, a P102A substitution, an A149C substitution, an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, an L373R substitution, an S215P substitution, an I379V substitution, an M447V substitution, a Y458C substitution, a K465Q substitution, a D486C substitution, and a D489C substitution.

[0111] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L ​​substitution, and an S290C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is substituted with a GS sequence.

[0112] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L ​​substitution, and an S290C substitution; the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence as shown in Seq ID NO.74; and the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12.

[0113] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L ​​substitution, and an S290C substitution; the P27 sequence of the pre-fusion hRSV F protein is replaced with the GS sequence shown in Seq ID NO.74; the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the pre-fusion hRSV F protein further includes at least one of an S46G substitution, an N67I substitution, an E92D substitution, a P102A substitution, an A149C substitution, an L373R substitution, an S215P substitution, an I379V substitution, an M447V substitution, a Y458C substitution, a K465Q substitution, a D486C substitution, and a D489C substitution.

[0114] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L ​​substitution, and an S290C substitution; the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence as shown in Seq ID NO.74; the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the pre-fusion hRSV F protein variant includes an amino acid sequence in which at least one of the amino acids of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence, or the 551-574 sequence is deleted continuously or intermittently.

[0115] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, a D486C substitution, and a D489C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is substituted with a GS sequence.

[0116] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, a D486C substitution, and a D489C substitution, and the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence as shown in Seq ID NO.74, and the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12.

[0117] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, a D486C substitution, and a D489C substitution, and the P27 sequence of the pre-fusion hRSV F protein is replaced with the GS sequence shown in Seq ID NO.74, and the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the pre-fusion hRSV F protein further includes at least one of an S46G substitution, an N67I substitution, an E92D substitution, a P102A substitution, an A149C substitution, an L373R substitution, an S215P substitution, an I379V substitution, an M447V substitution, a Y458C substitution, and a K465Q substitution.

[0118] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, a D486C substitution, and a D489C substitution; the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence as shown in Seq ID NO.74; the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the pre-fusion hRSV F protein variant includes an F2 sequence, an RR1 sequence, an RR2 sequence, a 525-529 sequence, or an amino acid sequence in which at least one of the amino acids of the 551-574 sequence is deleted consecutively or intermittently.

[0119] In some embodiments, the pre-fusion hRSV F protein variant includes an amino acid sequence in which at least one of the amino acids of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence, or the 551-574 sequence is deleted consecutively or intermittently.

[0120] In some embodiments, amino acids 98 to 109 of the hRSV F protein variant F2 sequence before fusion are continuously or intermittently missing at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid sequences.

[0121] In some embodiments, amino acids 137 to 144 of the RR1 sequence of the hRSV F protein variant before fusion are continuously or intermittently missing at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acid sequences.

[0122] In some embodiments, amino acids 504 to 524 of the hRSV F protein variant RR2 sequence before fusion are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 amino acid sequences.

[0123] In some embodiments, the amino acid sequence 525-529 of the hRSV F protein variant before fusion lacks at least 1, 2, 3, 4, or 5 amino acid sequences continuously or intermittently.

[0124] In some embodiments, the amino acid sequences 551-574 of the pre-fusion hRSV F protein variant are continuously or intermittently missing at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acid sequences.

[0125] The positions of the amino acid sequences described in the present disclosure, such as S46G substitution, E92D substitution, P102A substitution, A149C substitution, L373R substitution, I379V substitution, M447V substitution, Y458C substitution, K465Q substitution, D486C substitution, and D489C substitution are based on the full-length amino acid sequence of the wild-type hRSV F protein before fusion shown in Figure 1. For example, the S46G substitution is based on the wild-type hRSV F protein before fusion, and the S amino acid residue at position 46 of the full-length amino acid of the wild-type hRSV F protein before fusion shown in Figure 1 is replaced with a G amino acid residue, and the mutation occurs in the F2 sequence. For example, the 525-529 sequence is based on the wild-type hRSV F protein before fusion, and the RR2 sequence and the TM sequence are connected to the wild-type hRSV F protein before fusion shown in Figure 1. For example, sequences 551 to 574 are based on the wild-type hRSV F protein before fusion and are connected to the C-terminus of the TM sequence in the wild-type hRSV F protein before fusion shown in FIG1 .

[0126] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein is as shown in Seq ID NO.62, Seq ID NO.76, Seq ID NO.78, or comprises an amino acid sequence that is at least 80% identical to Seq ID NO.62, Seq ID NO.76, or Seq ID NO.78. For example, it can be, but is not limited to, an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 98% identical to Seq ID NO.62, Seq ID NO.76, or Seq ID NO.78.

[0127] In some embodiments, the amino acid sequence of the stabilized pre-fusion form of the hRSV F protein variant is as shown in Seq ID NO. 66, or comprises an amino acid sequence that is at least 80% identical to Seq ID NO. 66, for example, but not limited to, an amino acid sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO. 66.

[0128] In some embodiments, the amino acid sequence of the stabilized pre-fusion form of the hRSV F protein variant is as shown in Seq ID NO. 70, or comprises an amino acid sequence that is at least 80% identical to Seq ID NO. 70, for example, but not limited to, an amino acid sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO. 70.

[0129] In some embodiments, the amino acid sequence of the stabilized pre-fusion form of the hRSV F protein variant is as shown in Seq ID NO. 64, or comprises an amino acid sequence that is at least 80% identical to Seq ID NO. 64, for example, but not limited to, an amino acid sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO. 64.

[0130] In some embodiments, the amino acid sequence of the stabilized pre-fusion form of the hRSV F protein variant is as shown in Seq ID NO. 68, or comprises an amino acid sequence that is at least 80% identical to Seq ID NO. 68, for example, but not limited to, an amino acid sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO. 68.

[0131] In some embodiments, the amino acid sequence of the stabilized pre-fusion form of the hRSV F protein variant is as shown in Seq ID NO.72, or comprises an amino acid sequence that is at least 80% identical to Seq ID NO.72, for example, but not limited to, an amino acid sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.72.

[0132] In some embodiments, the pre-fusion hRSV F protein variant includes an amino acid sequence in which at least one of the amino acids of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence, or the 551-574 sequence is deleted consecutively or intermittently.

[0133] In some embodiments, amino acids 98 to 109 of the hRSV F protein variant F2 sequence before fusion are continuously or intermittently missing at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid sequences.

[0134] In some embodiments, amino acids 137 to 144 of the RR1 sequence of the hRSV F protein variant before fusion are continuously or intermittently missing at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acid sequences.

[0135] In some embodiments, amino acids 504 to 524 of the hRSV F protein variant RR2 sequence before fusion are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 amino acid sequences.

[0136] In some embodiments, the amino acid sequence 525-529 of the hRSV F protein variant before fusion lacks at least 1, 2, 3, 4, or 5 amino acid sequences continuously or intermittently.

[0137] In some embodiments, the amino acid sequences 551-574 of the pre-fusion hRSV F protein variant are continuously or intermittently missing at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acid sequences.

[0138] In some embodiments, the amino acid sequence of the hRSV F protein before fusion is as shown in Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.68, Seq ID NO.70, Seq ID NO.72, Seq ID NO.76, and Seq ID NO.78; and / or includes: amino acids 98 to 109 of the F2 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid sequences, and / or, amino acids 137 to 144 of the RR1 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acid sequences, and / or, amino acids 504 to 524 of the RR2 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acid sequences. and / or, the amino acids in the 525-529 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, or 5 amino acids; and / or, the amino acids in the 551-574 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acids.

[0139] In some embodiments, the amino acid sequence of the hRSV F protein before fusion is as shown in Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, and Seq ID NO.78; and / or includes: amino acids 98 to 109 of the F2 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid sequences, and / or, amino acids 137 to 144 of the RR1 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acid sequences, and / or, amino acids 504 to 524 of the RR2 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acid sequences. and / or, the amino acids in the 525-529 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, or 5 amino acids; and / or, the amino acids in the 551-574 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acids.

[0140] In some embodiments, the amino acid sequence of the hRSV F protein before fusion is as shown in Seq ID NO.62, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, and Seq ID NO.78; and / or includes: amino acids 98 to 109 of the F2 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid sequences, and / or amino acids 137 to 144 of the RR1 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acid sequences, and / or amino acids 504 to 524 of the RR2 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 amino acid sequences; and / or, amino acids in the 525-529 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, or 5 amino acid sequences; and / or, amino acids in the 551-574 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acid sequences.

[0141] In some embodiments, the multimerization element of the pre-fusion hRSV F protein can also be selected from the amino acid sequences shown in Seq ID NOs. 1-12 and Seq ID NOs. 14-15.

[0142] In some embodiments, the immune composition encoding human respiratory syncytial virus (hRSV) antigens is a nucleic acid immune composition; the nucleic acid immune composition comprises a nucleic acid molecule; the nucleic acid molecule comprises a DNA molecule and / or an RNA molecule.

[0143] In some embodiments, the DNA molecules include linear DNA molecules and / or circular DNA molecules.

[0144] In some embodiments, the RNA molecule comprises mRNA or circular RNA.

[0145] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.65, Seq ID NO.67, Seq ID NO.69, Seq ID NO.71, Seq ID NO.73, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.65, Seq ID NO.67, Seq ID NO.69, Seq ID NO.71, Seq ID NO.73, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103, for example, can be but is not limited to comprising a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.65, Seq ID NO.67, Seq ID NO.69, Seq ID NO.71, Seq ID NO.73, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103. No. 73, Seq ID No. 77, Seq ID No. 79, Seq ID Nos. 84-103 are at least 80%, 85%, 90%, 95% or 98% identical nucleotide sequences.

[0146] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103, for example, but not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103.

[0147] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of which is as shown in Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-87, Seq ID NOs.92-103, or comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-87, Seq ID NOs.92-103, for example, but not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-87, Seq ID NOs.92-103.

[0148] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103, for example, but not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103.

[0149] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.84-87, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.84-87, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.84-87.

[0150] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, for example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63.

[0151] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.77, Seq ID NO.96-99, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.77, Seq ID NO.96-99, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.77, Seq ID NO.96-99.

[0152] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.77, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.77, for example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.77.

[0153] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.79, Seq ID NO.100-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.79, Seq ID NO.100-103, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.79, Seq ID NO.100-103.

[0154] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.79, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.79, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.79.

[0155] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.65, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.65, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.65.

[0156] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.67, Seq ID NO.88-91, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.67, Seq ID NO.88-91, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.67, Seq ID NO.88-91.

[0157] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.67, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.67, for example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.67.

[0158] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.69, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.69, for example, but not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.69.

[0159] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.71, Seq ID NO.92-95, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.71, Seq ID NO.92-95, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.71, Seq ID NO.92-95.

[0160] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.71, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.71, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.71.

[0161] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.73, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.73, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.73.

[0162] In some embodiments, the nucleotide sequence of the dimerization element is as shown in Seq ID NO.36, Seq ID NO.42, or, after sequence optimization, the encoded amino acid sequence is as shown in Seq ID NO.1-2; the nucleotide sequence of the trimerization is as shown in Seq ID NO.37-40, Seq ID NO.43-46, Seq ID NO.13, or, after sequence optimization, the encoded amino acid sequence is as shown in Seq ID NO.3-12; the nucleotide sequence of the tetramerization element is as shown in Seq ID NO.41, Seq ID NO.47, and the encoded amino acid sequence after sequence optimization is as shown in Seq ID NO.14-15.

[0163] Furthermore, in some embodiments, the nucleotide sequence of the multimerization element in the open reading frame (ORF) can also be as shown in Seq ID NO.36-47 and Seq ID NO.13.

[0164] In some embodiments, nucleic acid molecules can optimize mRNA sequences by sequence optimization to improve properties related to expression efficacy after in vivo administration: for example, improving mRNA stability, increasing translation efficacy in target tissues, reducing the number of expressed truncated proteins, improving the folding of expressed proteins or preventing their misfolding, reducing the toxicity of expression products, reducing cell death caused by expression products, increasing and / or reducing protein aggregation, and obtaining mRNA with improved properties. The purpose of sequence optimization also includes: optimizing the formulation and delivery characteristics of nucleic acid-based therapeutics while maintaining structural and functional integrity; overcoming expression thresholds; increasing expression rates; half-life and / or protein concentrations; optimizing protein localization; and avoiding adverse biological responses such as immune responses and / or degradation pathways. Sequence optimization strategies include: (1) codon optimization based on codon frequencies in specific organs and / or host organisms to ensure proper folding and expression; (2) adjustment of G / C content to increase mRNA stability or reduce secondary structure; (3) minimization of tandemly repeated codons or baseruns that may impair gene construction or expression; (4) customization of transcriptional and translational control regions; and (5) reduction or elimination of problematic secondary structures within polynucleotides.

[0165] The “sequence identity” between two nucleotide sequences indicates the percentage of identical nucleotides between the sequences. The “sequence identity” between two amino acid sequences indicates the percentage of identical amino acids between the sequences.

[0166] The term "% identity" or similar terms refers to the percentage of identical nucleotides or amino acids between the compared sequences when optimally aligned. This percentage is purely statistical, and the differences between the two sequences may (but are not necessarily) randomly distributed over the entire length of the compared sequences. Comparison of two sequences is typically performed by comparing the sequences over a segment or "comparison window" after optimal alignment to identify local regions of corresponding sequences.

[0167] In some embodiments, based on the mRNA open reading frame sequence provided, those of ordinary skill in the art will be able to obtain the corresponding circular RNA open reading frame sequence, and according to the contents of the open literature such as CN202180048567.4, prepare the circular RNA complete sequence that can encode the same amino acid sequence. In some embodiments, based on the mRNA sequence provided, those of ordinary skill in the art will be able to obtain the corresponding DNA sequence (such as uracil is converted to thymine). Similarly, based on the DNA sequence provided, those of ordinary skill in the art will be able to obtain the corresponding RNA sequence (such as thymine is converted to uracil). In some embodiments, based on the RNA or DNA sequence provided, those of ordinary skill in the art will be able to obtain the corresponding amino acid sequence.

[0168] An open reading frame (ORF) as described in the present disclosure is a continuous stretch of DNA or RNA that begins with a start codon (eg, ATG or AUG) and ends with a stop codon (eg, TAA, TAG, or TGA, or UAA, UAG, or UGA).

[0169] In some embodiments, the mRNA described in the present disclosure consists of a sequence including, from the 5' end to the 3' end, a 5' cap, a 5' UTR, an ORF, a 3' UTR, and a 3' poly (A) tail.

[0170] The 5' untranslated region (UTR) as used herein refers to a sequence located immediately upstream (i.e., 5') of the start codon (i.e., the first codon of the mRNA transcript translated by the ribosome) of an mRNA that does not encode a polypeptide. When an RNA transcript is produced, the 5' UTR may comprise a promoter sequence. Such promoter sequences are known in the art. The RNA sequence of the 5' UTR is shown in one of Seq ID NO. 16, Seq ID NO. 17, or Seq ID NO. 18, or a 5' UTR sequence disclosed before the filing date of this disclosure may also be incorporated into the present disclosure.

[0171] The 3' untranslated region (UTR) as used herein refers to the sequence located downstream of the stop codon of an mRNA that does not encode a polypeptide. The RNA sequence of the 3' UTR is shown in one of Seq ID NO. 19, Seq ID NO. 20, or Seq ID NO. 21, or a 3' UTR sequence published before the filing date of this disclosure may be incorporated into the present disclosure.

[0172] The poly(A) tail, as described herein, is a sequence located downstream of the 3′ UTR of an mRNA that contains multiple consecutive adenosine monophosphates. The poly(A) tail can contain 10 to 300 adenosine monophosphates. In cells and / or in vivo, the poly(A) tail protects mRNA from enzymatic degradation and facilitates transcription termination and / or mRNA export from the nucleus and translation.

[0173] In some embodiments, the mRNA molecule comprises a self-replicating mRNA molecule or a non-self-replicating mRNA molecule.

[0174] In some embodiments, the mRNA described in the present disclosure is a self-replicating mRNA, which carries a sequence capable of expressing RNA polymerase (RNA-dependent RNA polymerase, RdRP). Specifically, the sequence design content of Chinese patent CN202110424124.2 on self-replicating mRNA is introduced into the present disclosure.

[0175] In some embodiments, the immunological composition comprises a delivery formulation.

[0176] In some embodiments, the delivery formulation comprises lipid nanoparticles or cationic liposomes.

[0177] In some embodiments, the components of the lipid nanoparticles include at least one of a protonatable cationic lipid, a structural lipid, a helper lipid, and a surfactant.

[0178] In some embodiments, the components of the lipid nanoparticles include, by weight, 40 to 60 parts of protonable cationic lipids, 20 to 40 parts of structural lipids, 10 to 30 parts of auxiliary lipids, and 0.5 to 5 parts of surfactants.

[0179] In some embodiments, the protonatable cationic lipid is selected from at least one of: Dlin-MC3-DMA, DODMA, C12-200, and DlinDMA.

[0180] In some embodiments, the structured lipid comprises cholesterol and / or a cholesterol derivative.

[0181] In some embodiments, the helper lipid comprises at least one of DSPC, DOPE, DOPC, DOPG, and DOPS.

[0182] In some embodiments, the surfactant includes at least one of PEG-DMG, PEG-DSPE, and TPGS.

[0183] In some embodiments, the liposome nanoparticles include, by mole percentage, 20% to 50% cationic lipid, for example, but not limited to 20%, 25%, 30%, 35%, 40%, 45% or 50%; 20% to 50% DOPG, for example, but not limited to 20%, 25%, 30%, 35%, 40%, 45% or 50%; 5% to 20% cholesterol, for example, but not limited to 5%, 10%, 15% or 20%; and 1% to 5% PEG-DMG, for example, but not limited to 1%, 2%, 3%, 4% or 5%.

[0184] In some embodiments, the liposome nanoparticles include, by mole percentage, 20% to 50% cationic lipid, such as but not limited to 20%, 25%, 30%, 35%, 40%, 45% or 50%; 20% to 50% DSCP, such as but not limited to 20%, 25%, 30%, 35%, 40%, 45% or 50%; 5% to 20% cholesterol, such as but not limited to 5%, 10%, 15% or 20%; and 1% to 5% PEG-DMG, such as but not limited to 1%, 2%, 3%, 4% or 5%.

[0185] In some embodiments, the liposome nanoparticles comprise, by mole percentage, 50% Dlin-MC3-DMA, 10% DOPG, 38.5% cholesterol, and 1.5% PEG-DMG.

[0186] In some embodiments, the liposome nanoparticles comprise, by mole percentage, 50% Dlin-MC3-DMA, 10% DSCP, 38.5% cholesterol, and 1.5% PEG-DMG.

[0187] In some embodiments, the present disclosure provides a method for preparing an immune composition according to any of the aforementioned embodiments, characterized in that it comprises: mixing the mRNA and a delivery formulation to form an immune composition; the delivery formulation comprises lipid nanoparticles or cationic liposomes.

[0188] In some embodiments, the immune composition preparation method comprises dissolving mRNA in a buffer solution to obtain an aqueous phase, measuring each lipid component of the liposome nanoparticles and dissolving them in an organic solvent to obtain an organic phase, mixing the aqueous phase and the organic phase, and removing the organic phase to obtain the immune composition.

[0189] In some embodiments, the volume ratio of the aqueous phase to the organic phase is 1:2 to 4, preferably 1:3.

[0190] In some embodiments, the buffer comprises citrate buffer or sodium acetate, preferably citrate buffer.

[0191] In some embodiments, the pH of the buffer is 3-7, preferably 4.

[0192] In some embodiments, the concentration of mRNA in the aqueous phase is 0.05 mg / mL to 0.5 mg / mL, preferably 0.1 mg / mL.

[0193] In some embodiments, the organic solvent is selected from C1-C4 lower carbon alcohols, preferably anhydrous ethanol.

[0194] In some embodiments, the concentration of the lipid component in the organic phase is 5 mg / mL to 7 mg / mL, preferably 6 mg / mL.

[0195] In some embodiments, microfluidics is used to mix the aqueous phase and the organic phase, and tangential flow is used to filter the organic solvent; preferably, the flow rate of the microfluidics is >3 ml / min, more preferably 12 mL / min.

[0196] In some embodiments, the method further comprises a concentration step after mixing, wherein the concentration step makes the final concentration of the mRNA 50 μg / mL to 200 μg / mL, preferably 100 μg / mL.

[0197] In some embodiments, the lipid nanoparticle has a diameter of less than about 200 nm. In some embodiments, the lipid nanoparticle has a diameter of less than about 150 nm. In some embodiments, the lipid nanoparticle has a diameter of less than 100 nm. In some embodiments, the lipid nanoparticle has a diameter of about 55 nm to about 90 nm.

[0198] In some embodiments, the immune composition comprising human respiratory syncytial virus (hRSV) antigen is a polypeptide immune composition. The polypeptide immune composition is an immune composition prepared by chemical synthesis technology or genetic engineering technology according to the amino acid sequence of a certain antigenic epitope known or predicted in the human respiratory syncytial virus antigen gene. In some embodiments, the polypeptide immune composition described in the present disclosure is an immune composition prepared by chemical synthesis technology according to the amino acid sequence of hRSVF protein before human respiratory syncytial virus fusion, combined with artificial mutation and transformation. In some embodiments, the polypeptide immune composition described in the present disclosure is obtained after fermentation according to the amino acid sequence of hRSVF protein before human respiratory syncytial virus fusion, combined with artificial mutation and transformation, and then by genetic engineering technology (such as constructing genetically engineered bacteria by genetic engineering technology means).

[0199] In some embodiments, the polypeptide immune composition comprises a pre-fusion hRSV F protein, and the amino acid sequence of the pre-fusion hRSV F protein is as follows: Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.68, Seq ID NO.70, Seq ID NO.72, Seq ID NO.76, Seq ID NO. NO.78; and / or including: amino acids at positions 98 to 109 of the F2 sequence continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; and / or amino acids at positions 137 to 144 of the RR1 sequence continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, or 8; and / or amino acids at positions 504 to 524 of the RR2 sequence continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, or 8; and / or, the amino acids in the 525-529 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, or 5 amino acids; and / or, the amino acids in the 551-574 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acids.

[0200] In some embodiments, the viral immune compositions described herein deliver the human respiratory syncytial virus antigen hRSV F protein gene into the human body via harmless microorganisms, inducing an immune response in the body's immune system. Important viruses used in cellular immunity induction experiments include variants of bovine poliovirus and poliovirus.

[0201] In some embodiments, the present disclosure provides an isolated mRNA, characterized in that the nucleic acid sequence of the coding region of the mRNA encodes a pre-fusion hRSV F protein, and the amino acid sequence of the pre-fusion hRSV F protein includes a TM sequence and a multimerization element; preferably, the amino acid sequence of the multimerization element is as shown in Seq ID NO.1-12, Seq ID NO.14-15; preferably, the amino acid sequence of the multimerization element is as shown in one of Seq ID NO.7 and Seq ID NO.12.

[0202] In some embodiments, in the isolated mRNA provided by the present disclosure, the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence; preferably, the GS sequence comprises (GnS)m, (GGGGS)o, GGSGGGGSGG, GGSGGGGG, GSGSGSGS, (Gly)p, (EAAAK)q, as shown in Seq ID NO.48-61, Seq ID NO.74 (wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; o is an integer from 1 to 5; p is an integer from 1 to 40; q is an integer from 1 to 5); preferably, the amino acid sequence of the GS sequence is as shown in Seq ID NO.74.

[0203] In some embodiments, the present disclosure provides an isolated mRNA, wherein the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S46G substitution, an N67I substitution, an E92D substitution, a P102A substitution, an A149C substitution, an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, an L373R substitution, an S215P substitution, an I379V substitution, an M447V substitution, a Y458C substitution, a K465Q substitution, a D486C substitution, and a D489C substitution.

[0204] In some embodiments, the present disclosure provides isolated mRNA, wherein the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, a D486C substitution, and a D489C substitution.

[0205] In some embodiments, the present disclosure provides an isolated mRNA, wherein the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L ​​substitution, and an S290C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is substituted with a GS sequence.

[0206] In some embodiments, the isolated mRNA provided herein comprises an amino acid sequence of the pre-fusion hRSV F protein comprising an S155C substitution, an S190F substitution, a V207L ​​substitution, and an S290C substitution; the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence as shown in Seq ID NO. 74; and the pre-fusion hRSV F protein comprises a multimerization element as shown in one of Seq ID NO. 7 and Seq ID NO. 12.

[0207] In some embodiments, the isolated mRNA provided herein comprises an amino acid sequence of the pre-fusion hRSV F protein comprising an S155C substitution, an S190F substitution, a V207L ​​substitution, and an S290C substitution; the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence as shown in Seq ID NO.74; the pre-fusion hRSV F protein comprises a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the pre-fusion hRSV F protein further comprises at least one of an S46G substitution, an N67I substitution, an E92D substitution, a P102A substitution, an A149C substitution, an L373R substitution, an S215P substitution, an I379V substitution, an M447V substitution, a Y458C substitution, a K465Q substitution, a D486C substitution, and a D489C substitution.

[0208] In some embodiments, the present disclosure provides an isolated mRNA, wherein the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, a D486C substitution, and a D489C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is substituted with a GS sequence.

[0209] In some embodiments, the present disclosure provides an isolated mRNA, wherein the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, a D486C substitution, and a D489C substitution, and the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence as shown in Seq ID NO. 74, and the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO. 7 and Seq ID NO. 12.

[0210] In some embodiments, the present disclosure provides an isolated mRNA, wherein the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L ​​substitution, an S290C substitution, a D486C substitution, and a D489C substitution, and the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence as shown in Seq ID NO.74, and the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the pre-fusion hRSV F protein further includes at least one of an S46G substitution, an N67I substitution, an E92D substitution, a P102A substitution, an A149C substitution, an L373R substitution, an S215P substitution, an I379V substitution, an M447V substitution, a Y458C substitution, and a K465Q substitution.

[0211] In some embodiments, the isolated mRNA provided herein, the pre-fusion hRSV F protein variant includes an amino acid sequence in which at least one of the amino acids of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence, or the 551-574 sequence is deleted consecutively or intermittently.

[0212] In some embodiments, the isolated mRNA provided herein has an amino acid sequence of the pre-fusion hRSV F protein as shown in Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.68, Seq ID NO.70, Seq ID NO.72, Seq ID NO.76, or Seq ID NO.78.

[0213] In some embodiments, the isolated mRNA provided herein has an amino acid sequence of the pre-fusion hRSV F protein as shown in Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, or Seq ID NO.78.

[0214] In some embodiments, the isolated mRNA provided herein has an amino acid sequence of the pre-fusion hRSV F protein as shown in Seq ID NO.62, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, or Seq ID NO.78.

[0215] In some embodiments, in the isolated mRNA provided herein, the multimerization element of the pre-fusion hRSV F protein can also be selected from the amino acid sequences shown in Seq ID NOs. 1-12 and Seq ID NOs. 14-15.

[0216] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of which is as shown in Seq ID NO.63, Seq ID NO.65, Seq ID NO.67, Seq ID NO.69, Seq ID NO.71, Seq ID NO.73, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103, or a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-87, Seq ID NOs.96-103. For example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-87, Seq ID NOs.96-103.

[0217] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103, for example, but not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103.

[0218] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of which is as shown in Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-87, Seq ID NOs.92-103, or a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-87, Seq ID NOs.92-103. For example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-87, Seq ID NOs.92-103.

[0219] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of which is as shown in Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-87, Seq ID NOs.96-103, or comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-87, Seq ID NOs.96-103. For example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-87, Seq ID NOs.96-103.

[0220] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NOs.84-87, or comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NOs.84-87, for example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NOs.84-87.

[0221] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, for example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63.

[0222] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.77, Seq ID NOs.96-99, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.77, Seq ID NOs.96-99, for example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.77, Seq ID NOs.96-99.

[0223] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of which is as shown in Seq ID NO.77, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.77, for example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.77.

[0224] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of which is as shown in Seq ID NO.79, Seq ID NO.100-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.79, Seq ID NO.100-103, for example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.79, Seq ID NO.100-103.

[0225] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of which is as shown in Seq ID NO.79, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.79, for example, but not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.79.

[0226] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.65, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.65, for example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.65.

[0227] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.67, Seq ID NOs.88-91, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.67, Seq ID NOs.88-91, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.67, Seq ID NOs.88-91.

[0228] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of which is as shown in Seq ID NO.67, or comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.67, for example, but not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.67.

[0229] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.69, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.69, for example, but not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.69.

[0230] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.71, Seq ID NOs.92-95, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.71, Seq ID NOs.92-95, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.71, Seq ID NOs.92-95.

[0231] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of which is as shown in Seq ID NO.71, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.71, for example, but not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.71.

[0232] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of which is as shown in Seq ID NO.73, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.73, for example, it can be, but is not limited to, a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.73.

[0233] Furthermore, in some embodiments, the nucleotide sequence of the multimerization element in the open reading frame (ORF) of the isolated mRNA can also be as shown in Seq ID NO.36-47 and Seq ID NO.13.

[0234] In some embodiments, the present disclosure provides an isolated DNA, characterized in that the DNA is obtained by reverse transcription of the mRNA or mRNA molecule nucleic acid isolated as described in any of the above items, or the DNA is a sequence or mRNA molecule that can transcribe the mRNA isolated as described in any of the above items.

[0235] In some embodiments, the isolated DNA is isolated linear DNA or isolated circular DNA.

[0236] In some embodiments, the present disclosure provides a biomaterial, comprising any one of an expression cassette, a vector, an engineered bacterium, or a cell line, wherein the biomaterial contains or expresses the mRNA isolated as described in any one of the foregoing items or the DNA isolated as described in any one of the foregoing items.

[0237] In some embodiments, the present disclosure provides a method comprising administering to a subject an effective amount of at least one of the immune composition described in any of the foregoing, the isolated mRNA described in any of the foregoing, the isolated DNA described in any of the foregoing, or the biological material described in any of the foregoing to induce a neutralizing antibody response against human syncytial virus in the subject.

[0238] In some embodiments, the method comprises administering to the subject at least twice an effective amount of at least one of the immunological composition of any one of the foregoing, the isolated mRNA of any one of the foregoing, the isolated DNA of any one of the foregoing, or the biological material of any one of the foregoing.

[0239] In some embodiments, the time interval between the first administration and the second administration in the at least two administrations is no less than 14 days.

[0240] In some embodiments, the subject is immunocompromised; in some embodiments, the subject is no older than 5 years old or no younger than 65 years old.

[0241] In some embodiments, the effective amount of the present disclosure is as low as 40 μg, 30 μg, 25 μg, 20 μg, 15 μg, 10 μg, 5 μg, 3 μg or 1 μg of any of the aforementioned immunological compositions, any of the aforementioned isolated mRNA or any of the aforementioned isolated DNA, or any of the aforementioned biological materials.

[0242] Example 1: Process for preparing LNPs from RNA

[0243] A lipid nanoparticle comprising RNA encoding a respiratory syncytial virus antigen, wherein the lipid nanoparticle comprises, by mole percentage, 50% of Dlin-MC3-DMA, 20% of DOPG, 29% of cholesterol and 1% of PEG-DMG.

[0244] The preparation method is as follows:

[0245] (a) RNA was dissolved in a pH 4 citrate buffer solution and the concentration was adjusted to 0.1 mg / ml to obtain an aqueous phase.

[0246] (b) Dlin-MC3-DMA, DOPG, cholesterol, and PEG-DMG were dissolved in anhydrous ethanol according to the formulated amounts, and the concentration of the lipid component in the organic phase was adjusted to 6 mg / mL to obtain an organic phase.

[0247] (c) The aqueous phase of step (a) and the organic phase of step (b) were mixed in a volume ratio of 1:3 using a microfluidic device at a flow rate of 12 mL / min. The mixture was immediately diluted 100-fold with a pH 7.4 PBS solution, and the ethanol component in the solution was removed by tangential flow filtration (TFF). The mixture was then concentrated to an mRNA concentration of 55 ug / ml to obtain lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens.

[0248] Example 2

[0249] Using luciferase as a reporter gene, the formulations of different vaccine vectors were studied by in vivo fluorescence imaging technology (as shown in Table 1 below).

[0250] Table 1

[0251] “MC3” refers to Dlin-MC3-DMA, and “+”: luciferase expression in mice was detected by the small animal in vivo fluorescence phase formation system after administration) The efficiency of delivering mRNA encoding the luciferase gene in mice, and the physical and chemical indicators of different composite preparations (see Example 1 for preparation method) were detected. The results are shown in Table 1. Through research, it was found that increasing the mass ratio of lipids to mRNA is beneficial to increasing the encapsulation efficiency of mRNA in lipid nanoparticles, thereby making it more stable. In addition, moderately increasing the content of polyethylene glycol (PEG) in the formula is beneficial to improving the expression efficiency of mRNA in vivo. Therefore, considering factors such as mRNA encapsulation efficiency and mRNA in vivo delivery efficiency, formulations 3 and 4 were selected for subsequent mRNA vaccine research.

[0252] Example 3

[0253] Table 2

[0254] Table 2 shows the ability of cationic lipid nanoparticles with different formulations to encapsulate luciferase mRNA and the resulting nanoparticle size data. All formulations were able to compress luciferase mRNA into nanoparticles with a diameter of less than 100 nm and a net neutral surface potential. Furthermore, all formulations were able to encapsulate at least 50% of the mRNA, demonstrating a reasonable in vivo delivery effect. "MC3" refers to Dlin-MC3-DMA.

[0255] Example 4

[0256] BALB / c mice (female, 5-6 weeks old, average body weight 20-25 g, purchased from Zhuhai Baishitong Biotechnology Co., Ltd.) were selected for vaccine immunogenicity evaluation.

[0257] The experimental animals were randomly divided into groups of 5 mice each. The immunization dose was 15 μg per mouse. A booster immunization of the same dose was given 2 weeks after vaccination. Twelve days after the second immunization, the cellular and humoral immune response indicators were measured.

[0258] Mouse lymphocytes were isolated using the following method: mice were sacrificed by cervical dislocation and immersed in 75% ethanol. The spleens were removed in a cleanroom. 4-5 mL of mouse lymphocyte separation buffer (bring to room temperature and shake well before use) were placed in a 35 mm culture dish. The spleen cells were triturated and immediately transferred to a 15 mL centrifuge tube. The tubes were centrifuged at 800 g for 30 minutes at room temperature in a swing-out rotor. After centrifugation, the lymphocyte layer was aspirated, 10 mL of RPMI 1640 medium was added, and the tubes were inverted to wash. The cells were then collected by centrifugation at room temperature. The experimental process is shown in Figure 3.

[0259] 1. ELISA detection of RSV-F protein-specific IgG antibodies in mouse serum (humoral immunity)

[0260] hRSV F protein wild type (HisTag) (2 mg / mL) diluted to 2 μg / mL with washing solution was added to a multi-well plate (100 μL per well) and coated overnight. After washing, 2% BSA solution was added for blocking.

[0261] All serum samples to be tested were diluted with washing solution in 10-fold gradients starting from 1:100 to 1:1,000,000. The negative control samples were kept consistent with the serum samples to be tested and were diluted at the same multiples. There were 6 gradient samples in total.

[0262] The prepared serum sample solution was added to the enzyme-labeled multi-well plate, incubated and washed, and the diluted enzyme-labeled antibody solution was added, incubated and washed, and color treatment was performed. The OD value was measured at 450nm / 630nm on a microplate reader.

[0263] The cutoff value was 2.1 times the arithmetic mean of the negative serum sample signal.

[0264] 2. Flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells (cellular immunity)

[0265] Isolated mouse lymphocytes were stimulated with the peptide library and incubated in a 37°C, 5% CO2 incubator for 72 hours. Stimulation was continued overnight with a BD Golgi 1 μg™ (containing Brefeldin A) protein transport inhibitor solution (containing BSA). The mouse lymphocyte suspension was centrifuged to collect the pellet.

[0266] Resuspend the mouse lymphocyte pellet, add specific monoclonal fluorescent antibodies, such as CD4, CD8, etc., incubate and centrifuge to retain the mouse lymphocyte pellet.

[0267] Add fixation / permeabilization solution, incubate and centrifuge to obtain mouse lymphocyte pellet. Add buffer to the mouse lymphocyte pellet, mix and centrifuge to obtain mouse lymphocyte pellet.

[0268] Resuspend the mouse lymphocyte pellet in staining buffer and add fluorescent antibodies to cytokines, such as IFN-γ and TNF-α. Incubate in the dark and centrifuge to retain the mouse lymphocyte pellet. Then resuspend the mouse lymphocyte pellet in staining buffer and analyze on a flow cytometer.

[0269] The expression of TNF-α in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry.

[0270] 3. Flow cytometry detection of IFN-γ+CD4+ and IFN-γ+CD8+ T cells (cellular immunity)

[0271] Isolated mouse lymphocytes were stimulated with the peptide library and incubated in a 37°C, 5% CO2 incubator for 72 hours. Stimulation was continued overnight with a BD Golgi 1 μg™ (containing Brefeldin A) protein transport inhibitor solution (containing BSA). The mouse lymphocyte suspension was centrifuged to collect the pellet.

[0272] Resuspend the mouse lymphocyte pellet, add specific monoclonal fluorescent antibodies, such as CD4, CD8, etc., incubate and centrifuge to retain the mouse lymphocyte pellet.

[0273] Add fixation / permeabilization solution, incubate and centrifuge to obtain mouse lymphocyte pellet. Add buffer to the mouse lymphocyte pellet, mix and centrifuge to obtain mouse lymphocyte pellet.

[0274] Resuspend the mouse lymphocyte pellet in staining buffer and add fluorescent antibodies to cytokines, such as IFN-γ and TNF-α. Incubate in the dark and centrifuge to retain the mouse lymphocyte pellet. Then resuspend the mouse lymphocyte pellet in staining buffer and analyze on a flow cytometer.

[0275] The expression of IFN-γ in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry.

[0276] 4. ELISA detection of IFN-γ and IL2 in cell culture supernatant (cellular immunity)

[0277] Separated mouse lymphocytes were taken, stimulated by adding peptide library, and cultured in a 37°C, 5% CO2 incubator for 72 hours. The mouse lymphocyte suspension was centrifuged and the supernatant was obtained.

[0278] The levels of IFN-γ and IL2 in the supernatant were detected using a mouse IL-2 ELISA kit (purchased from Xinbosheng Biotechnology Co., Ltd.) and a mouse IFN-γ ELISA kit (purchased from Xinbosheng Biotechnology Co., Ltd.).

[0279] 5. ELISA detection of IL4 and IL10 in cell culture supernatant (cellular immunity)

[0280] Isolated mouse lymphocytes were stimulated with the peptide library and incubated in a 37°C, 5% CO2 incubator for 72 hours. The mouse lymphocyte suspension was centrifuged and the supernatant was collected. The supernatant IL4 and IL10 levels were measured using a mouse IL-4 ELISA kit (purchased from Xinbosheng Biotechnology Co., Ltd.) and a mouse IL-10 ELISA kit (purchased from Xinbosheng Biotechnology Co., Ltd.).

[0281] 6. Neutralizing activity of serum

[0282] The neutralizing activity detection method of the sera of the immune composition group was as follows: HEp-2 cells were digested, the cell density was adjusted, and the cells were seeded into 96-well plates and cultured overnight.

[0283] Add each mouse serum dilution and virus dilution to the positive wells of the multi-well plate, add virus dilution to the negative wells, and then add diluted virus to the positive and negative wells of the multi-well plate, and culture and neutralize.

[0284] The neutralized products in the positive wells and negative wells of the multi-well plate were added to the multi-well plate containing the digested HEp-2 cells, respectively, and cultured; the neutralized products were aspirated, and DMEM+2% FBS medium was added to each well to continue culture.

[0285] Discard the supernatant and fix the cells with 4% paraformaldehyde in each well. Wash with PBS and block with a 1:1 mixture of 4% BSA and 0.2% triton. Discard the blocking solution and add the F6-6-488 antibody dilution solution. Incubate and wash. Shake the plate dry and read using a CTL instrument.

[0286] Example 5

[0287] The nucleotide sequences described in the table below are mRNA sequences. The mRNA sequences described in the table below were prepared into lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens according to the method described in Example 1.

[0288] Table 3

[0289] The mRNA in the mRNA immune composition encoding respiratory syncytial virus antigen, in addition to the reading frame sequence in the above table, also includes a 5' cap (m7Gppp (5')), a 5' UTR (as shown in Seq ID NO.16), a 3' UTR (as shown in Seq ID NO.19) and a 3' poly A tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced with a 5' pseudouracil.

[0290] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, an F protein (F-Protein) experimental group and a PBS blank control group were added into the experiment.

[0291] Sample Wt is an RNA lipid nanoparticle comprising an amino acid sequence encoding the wild-type RSV F protein; the amino acid sequence of the RSV F protein variant of sample F7-5 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C substitutions, and Fibritin Dominain is added to the C-terminus (amino acid sequence as shown in Seq ID NO.7); the amino acid sequence of the RSV F protein variant encoded by sample DS-Cav1 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C substitutions; the amino acid sequence of the RSV F protein variant encoded by sample DS-Cav1+Tric is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C substitutions, the TM sequence is deleted, and Fibritin Dominain is added to the C-terminus (amino acid sequence as shown in Seq ID NO.7).

[0292] The vaccine immunogenicity of the prepared lipid nanoparticles encoding RNA for respiratory syncytial virus antigens was evaluated according to the method of Example 4.

[0293] 1. Flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells

[0294] The results are shown in Figure 4. The results showed that there was no significant difference in TNF-α+CD8+ between the mRNA immune composition group and the F-protein immune composition group (P>0.01). There was no significant difference in TNF-α+CD4+ between the mRNA immune composition group and the F-protein immune composition group (P>0.01). Compared with the PBS group, both the mRNA immune composition group and the F-protein immune composition group significantly stimulated Th1 cellular immune responses (P<0.01).

[0295] 2. ELISA detection of IFN-γ and IL4 in cell culture supernatant

[0296] The IFN-γ detection results are shown in Figure 5. The results showed that the IFN-γ levels in the mRNA immune composition group were not significantly different from those in the F-protein immune composition group (P>0.01). Compared with the PBS group, both the mRNA immune composition group and the F-protein immune composition group significantly stimulated Th1 cellular immune responses.

[0297] The IL-4 assay results are shown in Figure 5. The results showed that, with the exception of the DS-Cav1 immune composition group, the IL-4 levels in the remaining mRNA immune composition groups were significantly higher than those in the F-protein immune composition group (P < 0.01). Compared with the PBS group, both the mRNA and F-protein immune composition groups significantly stimulated Th2 cellular immune responses.

[0298] 3. Neutralizing activity of serum

[0299] Fourteen days after the second vaccination, the RSV live virus tropism reduction experiment was performed to detect RSV neutralizing antibody titers in mouse serum, and the results are shown in Figure 6. Compared with the RSV F protein wild-type mRNA immune composition group and the other RSV F protein mutant mRNA immune composition groups, the RSV neutralizing antibody geometric mean titer in the F7-5 immune composition group was 10119.3, which was significantly higher than that in the other mRNA immune composition groups, the F-Protein immune composition group, and the PBS control group (P < 0.01).

[0300] In this example, the RSV F protein mutant mRNA immune composition group based on the wild-type RSV F protein with S155C / S190F / V207L / S290C substitutions retained the TM sequence and added a multimerization element (such as sample F7-5). The RSV neutralizing antibody titer in the mouse serum was significantly higher than that of only retaining the TM sequence (such as sample DS-Cav1) or only adding a multimerization element (such as sample DS-Cav1+Tric).

[0301] Example 6

[0302] According to the method described in Example 2, lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens were prepared, namely samples Wt, F7, F7-3, F7-1, and F7-2.

[0303] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample Wt is shown in Seq ID NO.25, and the encoded respiratory syncytial virus antigen is the wild type RSVF protein (amino acid sequence is shown in Seq ID NO.24).

[0304] The sequence of the RNA open reading frame in the lipid nanoparticles comprising RNA encoding a respiratory syncytial virus antigen described in sample F7 is shown in Seq ID NO.23, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence shown in Seq ID NO.22). The amino acid sequence of the RSV F protein variant encoded in sample F7 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74, the TM sequence is deleted, and Fibritin Dominain (amino acid sequence shown in Seq ID NO.7) is added to the C-terminus.

[0305] The sequence of the RNA open reading frame in the lipid nanoparticles comprising RNA encoding a respiratory syncytial virus antigen described in sample F7-3 is shown in Seq ID NO.29, and the encoded respiratory syncytial virus antigen is an RSV F protein mutant (amino acid sequence as shown in Seq ID NO.28). The amino acid sequence of the RSV F protein variant encoded in sample F7-3 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.28, the TM sequence is deleted, and GCN4 Dominain (amino acid sequence as shown in Seq ID NO.12) is added to the C-terminus.

[0306] The sequence of the RNA open reading frame in the lipid nanoparticles comprising RNA encoding a respiratory syncytial virus antigen described in sample F7-1 is shown in Seq ID NO.63, and the encoded respiratory syncytial virus antigen is an RSV F protein mutant (amino acid sequence shown in Seq ID NO.62). The amino acid sequence of the RSV F protein variant encoded in sample F7-1 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74, and Fibritin Dominain is added to the C-terminus (amino acid sequence shown in Seq ID NO.7).

[0307] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding a respiratory syncytial virus antigen described in sample F7-2 is shown in Seq ID NO.65, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence shown in Seq ID NO.64). The amino acid sequence of the RSV F protein variant encoded in sample F7-2 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, and the P27 sequence is replaced with the GS sequence shown in Seq ID NO.74.

[0308] The mRNA in the mRNA immune composition encoding respiratory syncytial virus antigen, in addition to the above-mentioned reading frame sequence, also includes a 5' cap (m7Gppp (5')), a 5' UTR (as shown in Seq ID NO.16), a 3' UTR (as shown in Seq ID NO.19) and a 3' poly A tail of 100 adenine nucleotides; and the uracil in the mRNA is replaced with a 5' pseudouracil.

[0309] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, F protein (F-Protein, purchased from Sino Biological, Beijing Yiqiao Shenzhou Science and Technology Co., Ltd.) was added to the experimental group and PBS blank control group.

[0310] The vaccine immunogenicity of the prepared lipid nanoparticles encoding RNA for respiratory syncytial virus antigens was evaluated according to the method of Example 4.

[0311] (1) ELISA detection of RSV-F protein-specific IgG in serum

[0312] 14 days after the second immunization, RSV-F protein-specific IgG antibodies in mouse serum were detected by ELISA. The serum was diluted from 100 times to 10 million times, and the OD450 was measured by indirect ELISA. The specific IgG antibody titers of mice in the RSV F protein mRNA immune composition group were statistically analyzed. The results showed (see Figure 7) that the IgG antibody titers of the RSV F protein wild-type mRNA immune composition group (Wt) and the RSV F protein mutant mRNA immune composition group (F7, F7-3, F7-1 and F7-2) were not significantly different from those in the F-protein immune composition group.

[0313] (2) Flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells

[0314] Fourteen days after immunization, splenic lymphocytes were isolated from the mice, and the expression of TNF-α in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry. The results are shown in Figure 8.

[0315] The results showed that the TNF-α+CD8+ in the F7-3 and F7-2 immune composition groups were significantly higher than that in the F-protein immune composition group (P<0.01). There was no significant difference in TNF-α+CD4+ between the mRNA immune composition group and the F-protein immune composition group (P>0.01). The TNF-α+CD8+ / CD4+ in the RSV F protein wild-type mRNA immune composition group (Wt), the RSV F protein mutant mRNA immune composition groups (F7, F7-3, F7-1, and F7-2), and the F-protein immune composition group were significantly higher than those in the PBS group (P<0.01).

[0316] The above results show that the RSVF protein wild-type mRNA immune composition group (Wt), RSVF protein mutant mRNA immune composition group (F7, F7-3, F7-1 and F7-2) and F-protein immune composition group can significantly stimulate the Th1 cellular immune response of mice.

[0317] (3) ELISA detection of IFN-γ and IL-2 in the supernatant of spleen T lymphocyte culture medium

[0318] Fourteen days after immunization, the expression of IFN-γ and IL-2 in the lymphocyte supernatant was detected by ELISA. The results are shown in Figure 9.

[0319] The results showed that IFN-γ levels in the F7-3, F7-1, and F7-2 immune composition groups were significantly higher than those in the F-protein immune composition group (P < 0.01). IL-2 levels in the F7-3 and F7-2 immune composition groups were significantly higher than those in the F-protein immune composition group (P < 0.01). IFN-γ and IL-2 levels in the RSV F protein wild-type mRNA immune composition group (Wt), the RSV F protein mutant mRNA immune composition groups (F7, F7-3, F7-1, and F7-2), and the F-protein immune composition group were significantly higher than those in the PBS group (P < 0.01).

[0320] (4) ELISA detection of IL-4 and IL-10 in the supernatant of spleen T lymphocyte culture medium

[0321] Fourteen days after immunization, the expression of IL-4 and IL-10 in the lymphocyte supernatant was detected by ELISA. The results are shown in Figure 10. The results showed that the IL-4 levels in the F7-3 and F7-2 immune composition groups were significantly higher than those in the F-protein immune composition group (P < 0.01). The IL-10 levels in the F7-1 immune composition group were significantly higher than those in the F-protein immune composition group (P < 0.01). The IL-4 and IL-10 levels in the RSV F protein wild-type mRNA immune composition group (Wt), the RSV F protein mutant mRNA immune composition groups (F7, F7-3, F7-1, and F7-2), and the F-protein immune composition group were significantly higher than those in the PBS group (P < 0.01).

[0322] The above results show that the RSVF protein wild-type mRNA immune composition group (Wt), RSVF protein mutant mRNA immune composition group (F7, F7-3, F7-1 and F7-2) and F-protein immune composition group can significantly stimulate the Th2 cellular immune response of mice.

[0323] (5) RSV neutralizing antibody titer in serum

[0324] 14 days after the second immunization, the RSV live virus tropism reduction experiment was used to detect the RSV neutralizing antibody titer in the mouse serum. As shown in Figure 11, compared with the RSV F protein wild-type mRNA immune composition group (Wt), RSV F protein mutant mRNA immune composition groups (F7-3, F7 and F7-2), and F-protein immune composition group, the RSV neutralizing antibody geometric mean titer of the F7-1 immune composition group was 36162, which was significantly higher than that of the other mRNA immune composition groups (P < 0.01).

[0325] In this example, the RSV F protein mutant mRNA immune composition group is based on the wild-type RSV F protein, with S155C / S190F / V207L / S290C substitutions, D486C / D489C substitutions, and the P27 sequence replaced by the GS sequence shown in Seq ID NO. 74. When the TM sequence is retained and the multimerization element is added (such as sample F7-1), the RSV neutralizing antibody titer in the mouse serum is significantly higher than that of only retaining the TM sequence (such as sample F7-2) or only adding the multimerization element (such as sample F7).

[0326] Example 7

[0327] According to the method described in Example 2, lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens were prepared, namely samples Wt, F7-1, DS-Cav1 and mVRC-1 (v2).

[0328] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample Wt is shown in Seq ID NO.25, and the encoded respiratory syncytial virus antigen is the wild type RSVF protein (amino acid sequence is shown in Seq ID NO.24).

[0329] The sequence of the RNA open reading frame in the lipid nanoparticles comprising RNA encoding a respiratory syncytial virus antigen described in sample F7-1 is shown in Seq ID NO.63, and the encoded respiratory syncytial virus antigen is an RSV F protein mutant (amino acid sequence shown in Seq ID NO.62). The amino acid sequence of the RSV F protein variant encoded in sample F7-1 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74, and Fibritin Dominain is added to the C-terminus (amino acid sequence shown in Seq ID NO.7).

[0330] The sequence of the RNA open reading frame in the lipid nanoparticle containing RNA encoding a respiratory syncytial virus antigen described in sample DS-Cav1 is shown in Seq ID NO. 27, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence shown in Seq ID NO. 26). The amino acid sequence of the RSV F protein variant encoded by sample DS-Cav1 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C substitutions.

[0331] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample mVRC-1 (v2) is shown in Seq ID NO.31, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.30).

[0332] The mRNA in the RNA immune composition encoding respiratory syncytial virus antigen, in addition to the above-mentioned reading frame sequence, also includes a 5' cap (m7Gppp (5')), a 5' UTR (as shown in Seq ID NO.16), a 3' UTR (as shown in Seq ID NO.19) and a 3' polyA tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced with a 5' pseudouracil.

[0333] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, an F protein (F-Protein) experimental group and a PBS blank control group were added into the experiment.

[0334] The vaccine immunogenicity of the prepared lipid nanoparticles encoding RNA for respiratory syncytial virus antigens was evaluated according to the method of Example 4.

[0335] (1) Flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells

[0336] Fourteen days after immunization, spleen lymphocytes were isolated from the mice, and the expression of TNF-α in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry. The results are shown in Figure 12.

[0337] The results showed that the mRNA immune composition group had no significant difference in TNF-α+CD8+ compared to the F-protein immune composition group (P>0.01). There was no significant difference in TNF-α+CD4+ compared to the F-protein immune composition group (P>0.01). Compared with the PBS group, both the mRNA immune composition group and the F-protein immune composition group significantly stimulated Th1 cellular immune responses.

[0338] (2) Flow cytometry detection of IFN-γ+CD4+ and IFN-γ+CD8+ T cells

[0339] Fourteen days after immunization, spleen lymphocytes were isolated from the mice, and the expression of IFN-γ+ in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry. The results are shown in Figure 13.

[0340] The results showed that the mRNA immune composition group had significantly higher IFN-γ+CD8+ levels than the F-protein immune composition group (P < 0.01). Except for the mVRC-1(v2) immune composition group, the remaining mRNA immune composition groups had significantly higher IFN-γ+CD4+ levels than the F-protein immune composition group (P < 0.01). Compared with the PBS group, both the mRNA and F-protein immune composition groups significantly stimulated Th1 cellular immune responses.

[0341] (3) ELISA detection of IFN-γ and IL-2 in the supernatant of spleen T lymphocyte culture medium

[0342] Fourteen days after immunization, ELISA was used to measure the expression of IFN-γ and IL-2 in the lymphocyte supernatant. The results are shown in Figure 14. The results showed that there was no significant difference in IFN-γ between the mRNA immune composition group and the F-protein immune composition group (P>0.01). Except for the Wt immune composition group, IL-2 levels in the remaining mRNA immune composition groups were significantly elevated compared to the F-protein immune composition group (P<0.01). Compared with the PBS group, both the mRNA immune composition group and the F-protein immune composition group significantly stimulated Th1 cellular immune responses.

[0343] (4) ELISA detection of IL-4 and IL-10 in the supernatant of spleen T lymphocyte culture medium

[0344] Fourteen days after immunization, ELISA was used to detect the expression of IL-4 and IL-10 in lymphocyte supernatants. The results are shown in Figure 15. The results showed that, with the exception of the DS-Cav1 immune composition group, IL-4 levels in the remaining mRNA immune composition groups were significantly higher than those in the F-protein immune composition group (P < 0.01). With the exception of the DS-Cav1 immune composition group, IL-10 levels in the remaining mRNA immune composition groups were significantly higher than those in the F-protein immune composition group (P < 0.01). Compared with the PBS group, both the mRNA immune composition group and the F-protein immune composition group significantly stimulated Th2 cellular immune responses.

[0345] (5) RSV neutralizing antibody titer in serum

[0346] Fourteen days after the second immunization, the RSV live virus tropism reduction experiment was performed to measure RSV neutralizing antibody titers in mouse serum. As shown in Figure 16, the RSV neutralizing antibody geometric mean titer of the F7-1 immune composition group was 20821, significantly higher than that of the other mRNA immune composition groups (P < 0.01).

[0347] Example 8

[0348] According to the method described in Example 2, lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens were prepared, namely samples Wt, F7-1, F7-2, F7-3, F7-4, F7-5 and F7-6.

[0349] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample Wt is shown in Seq ID NO.25, and the encoded respiratory syncytial virus antigen is the wild type RSVF protein (amino acid sequence is shown in Seq ID NO.24).

[0350] The sequence of the RNA open reading frame in the lipid nanoparticles comprising RNA encoding a respiratory syncytial virus antigen described in sample F7-1 is shown in Seq ID NO.63, and the encoded respiratory syncytial virus antigen is an RSV F protein mutant (amino acid sequence shown in Seq ID NO.62). The amino acid sequence of the RSV F protein variant encoded in sample F7-1 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74, and Fibritin Dominain is added to the C-terminus (amino acid sequence shown in Seq ID NO.7).

[0351] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding a respiratory syncytial virus antigen described in sample F7-2 is shown in Seq ID NO.65, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence shown in Seq ID NO.64). The amino acid sequence of the RSV F protein variant encoded in sample F7-2 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, and the P27 sequence is replaced with the GS sequence shown in Seq ID NO.74.

[0352] The sequence of the RNA open reading frame in the lipid nanoparticles comprising RNA encoding a respiratory syncytial virus antigen described in sample F7-3 is shown in Seq ID NO.67, and the encoded respiratory syncytial virus antigen is an RSV F protein mutant (amino acid sequence shown in Seq ID NO.66). The amino acid sequence of the RSV F protein variant encoded in sample F7-3 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74, and GCN4 Dominain is added to the C-terminus (amino acid sequence shown in Seq ID NO.12).

[0353] The sequence of the RNA open reading frame in the lipid nanoparticles comprising RNA encoding a respiratory syncytial virus antigen described in sample F7-4 is shown in Seq ID NO.69, and the encoded respiratory syncytial virus antigen is an RSV F protein mutant (amino acid sequence shown in Seq ID NO.68). The amino acid sequence of the RSV F protein variant encoded in sample F7-4 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74, and Fibritin Dominain (amino acid sequence shown in Seq ID NO.7) is added to the C-terminus.

[0354] The sequence of the RNA open reading frame in the lipid nanoparticles comprising RNA encoding a respiratory syncytial virus antigen described in sample F7-5 is shown in Seq ID NO.71, and the encoded respiratory syncytial virus antigen is a RSVF protein mutant (amino acid sequence is shown in Seq ID NO.70). The amino acid sequence of the RSVF protein variant encoded by sample F7-5 is based on the RSVF protein wild type, with S155C / S190F / V207L / S290C substitutions, and Fibritin Dominain is added to the C-terminus (amino acid sequence is shown in Seq ID NO.7).

[0355] The sequence of the RNA open reading frame in the lipid nanoparticles comprising RNA encoding a respiratory syncytial virus antigen described in sample F7-6 is shown in Seq ID NO.73, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence shown in Seq ID NO.72). The amino acid sequence of the RSV F protein variant encoded in sample F7-6 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, and Fibritin Dominain is added to the C-terminus (amino acid sequence shown in Seq ID NO.7).

[0356] The mRNA in the RNA immune composition encoding respiratory syncytial virus antigen, in addition to the above-mentioned reading frame sequence, also includes a 5' cap (m7Gppp (5')), a 5' UTR (as shown in Seq ID NO.16), a 3' UTR (as shown in Seq ID NO.19) and a 3' polyA tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced with a 5' pseudouracil.

[0357] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, a PBS blank control group was added into the experiment.

[0358] The vaccine immunogenicity of the prepared lipid nanoparticles encoding RNA for respiratory syncytial virus antigens was evaluated according to the method of Example 4.

[0359] (1) Flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells

[0360] Fourteen days after immunization, spleen lymphocytes were isolated from the mice, and the expression of TNF-α in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry. The results are shown in Figure 17.

[0361] The results showed that the F7-1 immune composition group had no significant difference in TNF-α+CD8+ compared to the other mRNA immune composition groups (P>0.01). No significant increase in TNF-α+CD4+ was detected in the mRNA immune composition group (P>0.01). Compared with the PBS group, both mRNA immune composition groups significantly stimulated Th1 cell immune responses.

[0362] (2) Flow cytometry detection of IFN-γ+CD4+ and IFN-γ+CD8+ T cells

[0363] Fourteen days after immunization, spleen lymphocytes from the mice were isolated, and the expression of IFN-γ+ in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry. The results are shown in Figure 18.

[0364] The results showed that, with the exception of the F7-2 immune composition group, the F7-1 immune composition group showed no significant difference in IFN-γ+CD8+ compared to the other mRNA immune composition groups. No significant increase in IFN-γ+CD4+ was detected in the mRNA immune composition group (P>0.01). Compared with the PBS group, all mRNA immune composition groups significantly stimulated Th1 cellular immune responses.

[0365] (3) ELISA detection of IFN-γ and IL-2 in the supernatant of spleen T lymphocyte culture medium

[0366] Fourteen days after immunization, ELISA was used to detect the expression of IFN-γ and IL-2 in lymphocyte supernatants. The results are shown in Figure 19. The results showed that, with the exception of the F7-4 and F7-6 immune composition groups, there was no significant difference in IFN-γ levels in the F7-1 immune composition group compared with the other mRNA immune composition groups. IL-2 levels were significantly higher in the F7-1 immune composition group than in the other mRNA immune composition groups (P < 0.01). Compared with the PBS group, all mRNA immune composition groups significantly stimulated Th1 cellular immune responses.

[0367] (4) ELISA detection of IL-4 and IL-10 in the supernatant of spleen T lymphocyte culture medium

[0368] Fourteen days after immunization, ELISA was used to detect IL-4 and IL-10 expression in lymphocyte supernatants. The results are shown in Figure 20. The results showed that, with the exception of the Wt and F7-3 immune composition groups, IL-4 levels in the F7-1 immune composition group were not significantly different from those in the other mRNA immune composition groups. With the exception of the Wt, F7-2, and F7-3 immune composition groups, IL-10 levels in the F7-1 immune composition group were significantly elevated compared to those in the other mRNA immune composition groups. Compared to the PBS group, all mRNA immune composition groups significantly stimulated Th2 cellular immune responses.

[0369] (5) RSV neutralizing antibody titer in serum

[0370] 14 days after the second immunization, the RSV live virus tropism reduction experiment was used to detect the RSV neutralizing antibody titer in the mouse serum. The results are shown in Figure 21. As shown in the figure, compared with the mRNA immune composition group, the RSV neutralizing antibody geometric mean titer of the F7-1 immune composition group was 20730, which was significantly higher than that of the other mRNA immune composition groups and the F-Protein immune composition group (P<0.01); the RSV neutralizing antibody geometric mean titer of the F7-3 immune composition group was 16026, and the RSV neutralizing antibody geometric mean titer of the F7-5 immune composition group was 10871, which was significantly higher than that of the Wt, F7-2, F7-4, F7-6 immune composition groups and the F-Protein immune composition group (P<0.01).

[0371] Example 9

[0372] According to the method described in Example 2, lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens were prepared, namely samples Wt, F7-1, F7-a and F7-b.

[0373] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample Wt is shown in Seq ID NO.25, and the encoded respiratory syncytial virus antigen is the wild type RSVF protein (amino acid sequence is shown in Seq ID NO.24).

[0374] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample F7-1 is shown in Seq ID NO.63, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.62).

[0375] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample F7-a is shown in Seq ID NO.77, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.76).

[0376] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample F7-b is shown in Seq ID NO.79, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.78).

[0377] In addition to the above-mentioned nucleotide ORF sequence, the sequences of these RNA vaccines also include a 5' cap (m7Gppp(5')), a 5'UTR (as shown in Seq ID NO.16), a 3'UTR (as shown in Seq ID NO.19) and a 3'polyA tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced with a 5'pseudouracil.

[0378] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, a PBS blank control group was added into the experiment.

[0379] The RSV neutralizing antibody titer in serum was evaluated for the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens according to the method of Example 4.

[0380] Fourteen days after the second immunization, RSV live virus tropism reduction experiments were performed to measure RSV neutralizing antibody titers in mouse serum. As shown in Figure 22, compared with the Wt immune composition group, the RSV neutralizing antibody geometric mean titers in the F7-1 immune composition group, the F7-a immune composition group, and the F7-b immune composition group all exceeded 18,000, significantly higher than those in the Wt immune composition group (P < 0.01).

[0381] Example 10

[0382] The nucleotide sequences described in the table below are mRNA sequences. The mRNAs shown in the table below were transfected into cells, and the expression of RSV F full-length protein in the cells was detected. The results are shown in the table below.

[0383] The detailed method is as follows: HEK293 cells were lysed 24 hours after transfection of each mRNA, and the target protein was specifically detected by SDS-PAGE immunoblotting according to the loading amount of 10 μg of total protein. In this embodiment, anti-RSVF protein antibody was used as the primary antibody and goat anti-mouse-HRP antibody was used as the secondary antibody for incubation, and then color was developed. When analyzing the protein expression detection results, internal reference β-actin was used for standardization and quantification. At the same time, cells that were not transfected with mRNA were set as negative controls to compare the differences in protein expression after cells were transfected with different mRNAs. The test results showed that the expression of the full length of RSVF protein could be detected. The expression level of each sequence was measured as a relative OD value, as shown in the table below; the relative OD value was calculated as follows: sample OD value / OD value of sample 1.

[0384] Table 4

[0385] Example 11

[0386] The RNA sequences numbered 1 to 9 in Table 4 of Example 10 were prepared into lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens according to the method described in Example 2, and were respectively prepared as samples 01 to 09.

[0387] In addition to the above-mentioned nucleotide sequences, the sequences of these RNA vaccines also include a 5' cap (m7Gppp(5')) and a 3' polyA tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced with a 5' pseudouracil.

[0388] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, a PBS blank control group was added into the experiment, and the sample Wt prepared according to Example 9 was expected.

[0389] The RSV neutralizing antibody titer in serum was evaluated for the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens according to the method of Example 4.

[0390] Fourteen days after the second immunization, RSV live virus tropism reduction assays were performed to measure RSV neutralizing antibody titers in mouse serum. As shown in Figure 23, compared with the Wt immune composition group, the geometric mean RSV neutralizing antibody titers of samples 01 to 09 all exceeded 10,000, significantly higher than those of the Wt immune composition group (P < 0.01). Furthermore, the geometric mean RSV neutralizing antibody titer of sample 09 was slightly higher than that of the other samples 01 to 08.

[0391] Example 12

[0392] According to the method described in Example 2, lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens were prepared, namely samples Wt, F124 to F138.

[0393] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample Wt is shown in Seq ID NO.25, and the encoded respiratory syncytial virus antigen is the wild type RSVF protein (amino acid sequence is shown in Seq ID NO.24).

[0394] The sequences of the RNA open reading frames in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens described in samples 124 to 128 are shown in Seq ID NO.63 and Seq ID NO.84 to 87, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.62).

[0395] The sequences of the RNA open reading frames in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens described in samples 129 to 133 are shown in Seq ID NO.67 and Seq ID NO.88 to 91, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.66).

[0396] The sequences of the RNA open reading frames in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens described in samples 134 to 138 are shown in Seq ID NO.71 and Seq ID NO.92 to 95, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.70).

[0397] The sequences of the RNA open reading frames in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens described in samples 139 to 143 are shown in Seq ID NO.77 and Seq ID NO.96 to 99, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.76).

[0398] The sequences of the RNA open reading frames in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens described in samples 144 to 148 are shown in Seq ID NO.79 and Seq ID NO.100 to 103, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.78).

[0399] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen is shown in Seq ID NO.103, and the encoded respiratory syncytial virus antigen is an RSV F protein mutant (amino acid sequence is shown in Seq ID NO.78).

[0400] In addition to the above-mentioned nucleotide ORF sequence, the sequences of these RNA vaccines also include a 5' cap (m7Gppp(5')), a 5'UTR (as shown in Seq ID NO.16), a 3'UTR (as shown in Seq ID NO.19) and a 3'polyA tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced with a 5'pseudouracil.

[0401] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, a PBS blank control group was added into the experiment.

[0402] The RSV neutralizing antibody titer in serum was evaluated for the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens according to the method of Example 4.

[0403] Fourteen days after the second immunization, RSV live virus tropism reduction assays were performed to measure RSV neutralizing antibody titers in mouse serum. As shown in Figures 24-26 , compared with the Wt immune composition group, the geometric mean RSV neutralizing antibody titers in the F124-F148 immune composition groups all exceeded 10,000, significantly higher than those in the Wt immune composition group (P < 0.01).

[0404] The RSV neutralizing antibody titers of samples 124-128 and 140-148, whose respiratory syncytial virus antigens were edited as RSV F protein mutants as shown in Seq ID NO.62, Seq ID NO.76 and Seq ID NO.78, were higher than those of other samples.

[0405] Example 13

[0406] BALB / c mice (female, 5 weeks old, average weight about 19 g, purchased from Zhuhai Baishitong Biotechnology Co., Ltd.) were selected for vaccine immunogenicity evaluation. The experimental animals were randomly divided into 5 groups, with 6 mice in each group. The dosing regimens were as follows: (1) Vehicle group: intramuscular injection of 50 μg / mouse PBS buffer containing empty lipid nanoparticles; (2) F protein group: intramuscular injection of 50 μg / mouse PBS buffer containing 0.05 μg pre-fusion hRSV F protein; (3) F7-1 (5 μg) group: intramuscular injection of 25 μg / mouse lipid nanoparticle PBS buffer containing 5 μg RNA encoding respiratory syncytial virus antigen, wherein the sequence of the RNA open reading frame is shown in Seq ID NO.63; (4) F7-1 (15 μg) group: intramuscular injection of 75 μg / mouse lipid nanoparticle PBS buffer containing 15 μg RNA encoding respiratory syncytial virus antigen, wherein the sequence of the RNA open reading frame is shown in Seq ID NO.63; (5) Health group: no drug administration. The same dose of booster immunization was given on the 21st day after vaccination, and serum samples were collected after the 35th day after vaccination. On the 40th day after vaccination, the animals were sacrificed and lung tissues were collected. On the 35th day after vaccination, mice in groups 1 to 4 were inoculated with RSV / A2 virus by nasal drops. During the experiment, the weight and weight changes of mice were monitored, as well as the neutralizing activity of RSV-F protein-specific IgG antibodies and serum, the detection of lung tissue virus titers in mice after RSV infection, and the pathological detection of lung tissues in mice after RSV infection were monitored. For the detection method of RSV-F protein-specific IgG antibodies and serum neutralizing activity, please refer to Example 4 of the present disclosure. HE staining was used to evaluate lung tissue lesions, perivascular, peribronchial, alveolar, and interstitial lung inflammation. Plaque assay was used to detect lung tissue virus titers.

[0407] Lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens were prepared according to the method described in Example 2, designated sample F7-1. In addition to the aforementioned nucleotide ORF sequence, the sequences of these RNA vaccines also included a 5' cap (m7Gppp(5')), a 5' UTR (as shown in Seq ID NO. 16), a 3' UTR (as shown in Seq ID NO. 19), and a 3' polyA tail of 100 adenine nucleotides; and the uracil of the mRNA was replaced with a 5' pseudouracil.

[0408] (1) Mouse weight and weight changes

[0409] The body weight and weight changes of mice during the experiment are shown in Figures 27 and 28. From day 2 to day 5 after the first vaccination, the body weight of the F7-1 (5 μg) and F7-1 (15 μg) immunized groups decreased significantly (Figure 27). The F7-1 (5 μg) immunized group had a body weight decrease of approximately 5% on day 2 after the first vaccination, while the F7-1 (15 μg) immunized group had a body weight decrease of approximately 10% on day 2 after the first vaccination (Figure 28). One day after the second vaccination (day 22 after the first vaccination), the body weight of the F7-1 (5 μg) and F7-1 (15 μg) immunized groups decreased significantly (Figure 27). The F7-1 (5 μg) immunized group had a body weight decrease of approximately 5% on day 2 after the second vaccination, while the F7-1 (15 μg) immunized group had a body weight decrease of approximately 10% on day 2 after the second vaccination (Figure 28). Compared with the weight before intranasal inoculation of RSV / A2 virus, the body weight of the Vehile immunization group decreased by about 3%, the body weight of the Fprotein immunization group decreased by about 5%, the body weight of the F7-1 (5 μg) immunization group decreased by about 4%, and the body weight of the F7-1 (15 μg) immunization group increased by 1% on the 5th day after the infection.

[0410] (2) ELISA detection of RSV-F protein-specific IgG in serum

[0411] 35 days after the first vaccination, RSV-F protein-specific IgG antibodies in mouse serum were detected by ELISA. The serum was diluted from 100 times to 8 million times, and OD450 was measured by indirect ELISA.

[0412] A sample was considered positive if its OD450 value was ≥ 2 times the mean OD450 value of the negative control group at the minimum dilution factor (1:100) (Bao-Zhong Wang, et al., PLoS ONE, 2010; Teena Mohan, et al., J Control Release, 2016). The final titer for serum samples from the F7-1 (15 μg) immunization group was reached when diluted to 8 million times.

[0413] The statistical results of RSV-F protein-specific IgG antibody titers in serum are shown in Figure 29. The results show that the F7-1 (15 μg) immunization group had the highest IgG titer GMT value. IgG antibody titers in the F7-1 (5 μg) and F7-1 (15 μg) immunization groups were significantly higher than those in the F protein immunization group.

[0414] (3) RSV neutralizing antibody titer in serum

[0415] 35 days after the first vaccination, RSV-A / B strain virus plaque reduction experiment was used to detect RSV neutralizing antibody titers in mouse serum. As shown in the left figure of Figure 30, for RSV-A2 strain, the neutralizing antibody titers of F7-1 (5μg) (GMT=20030) and F7-1 (15μg) (GMT=27335) immunization groups were significantly higher than those of F protein (GMT=54) immunization group (P<0.05), and there was no significant difference between F7-1 (5μg) immunization group and F7-1 (15μg) immunization group, indicating that there was no significant difference between high and low dose groups of F7-1 vaccine; as shown in the right figure of Figure 30, for RSV-18537 strain, the neutralizing antibody titers of F7-1 (5μg) (GMT=4177) and F7-1 (15μg) (GMT=9392) immunization groups were significantly higher than those of F protein (GMT=54) immunization group. The neutralizing antibody titer of the F7-1 (5 μg) and F7-1 (15 μg) immunization groups was significantly increased (P < 0.05), and there was no significant difference in the neutralizing antibody titer between the F7-1 (5 μg) and F7-1 (15 μg) immunization groups (P > 0.05), indicating that there was no significant difference between the high and low dose F7-1 groups.

[0416] (4) Virus titer in lung tissue of mice after RSV infection

[0417] After 5 days of RSV infection, the plaque reduction neutralization test (Plaque Reduction Neutralization Test) was used to measure the RSV virus titer in the right lung tissue homogenate of mice after intranasal inoculation of RSV / A2 virus (see Figure 31). The virus titer in the lung tissue of the Vehicle immunization group was significantly higher than that of the Fprotein, F7-1 (5μg), F7-1 (15μg) and Health groups. Among them, the F7-1 (5μg), F7-1 (15μg) and Health groups were all at the lower limit of quantitation (LLOQ). The results showed that F protein (RSV inactivated vaccine), F7-1 (5μg) and F7-1 (15μg) mRNA vaccines can significantly reduce the virus titer in the lung tissue of the immunized mice.

[0418] (5) Lung histopathology of mice after RSV infection

[0419] After 5 days of RSV infection, HE staining was used to evaluate lung tissue lesions (perivascular, peribronchial, alveolar, and interstitial lung inflammation). As shown in Figure 32, the perivascular, peribronchial, alveolar, and interstitial lung inflammation scores of the Fprotein immunization group were significantly higher than those of the Vehicle immunization group. The Vehicle, 007-5μg, and 007-15μg immunization groups all showed mild pathological reactions after RSV infection. In summary, these results indicate that the F7-1 (5μg) and F7-1 (15μg) immunization groups can induce high titers of IgG-specific antibodies and neutralizing antibodies, protecting animals from RSV infection without causing vaccine-enhanced respiratory disease (VERD).

[0420] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present disclosure, rather than to limit them. Although the present disclosure has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present disclosure.

Claims

1. An immune composition comprising or encoding a human respiratory syncytial virus antigen, characterized in that: The immune composition is selected from a nucleic acid immune composition, a polypeptide immune composition or a virus immune composition; Preferably, the antigen is a pre-fusion hRSV F protein, and the amino acid sequence of the pre-fusion hRSV F protein includes a TM sequence and a multimerization element; preferably, the amino acid sequence of the multimerization element is as shown in Seq ID NO.1-12 and Seq ID NO.14-15; preferably, the amino acid sequence of the multimerization element is as shown in one of Seq ID NO.7 and Seq ID NO.

12.

2. The immune composition according to claim 1, characterized in that The P27 sequence of the hRSV F protein before fusion is replaced with a GS sequence; preferably, the GS sequence comprises (GnS)m, (GGGGS)o, GGSGGGGSGG, GGSGGGGG, GSGSGSGS, (Gly)p, (EAAAK)q, Seq ID NO.48-61, Seq ID NO.74 (wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; o is an integer from 1 to 5; p is an integer from 1 to 40; q is an integer from 1 to 5); preferably, the amino acid sequence of the GS sequence is as shown in Seq ID NO.74; Preferably, the pre-fusion hRSV F protein includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, S155C substitution, S190F substitution, V207L ​​substitution, S290C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, K465Q substitution, D486C substitution, and D489C substitution.

3. The immune composition according to claim 1 or 2, characterized in that The amino acid sequence of the hRSV F protein before fusion includes at least one of S155C substitution, S190F substitution, V207L ​​substitution, S290C substitution, D486C substitution, and D489C substitution; Preferably, the amino acid sequence of the hRSV F protein before fusion includes at least one of S155C substitution, S190F substitution, V207L ​​substitution, S290C substitution, and / or the P27 sequence of the hRSV F protein before fusion is replaced with a GS sequence; Preferably, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L ​​substitution, and S290C substitution; the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74; the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; Preferably, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L ​​substitution, and S290C substitution; the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74; the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the hRSV F protein before fusion also includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, K465Q substitution, D486C substitution, and D489C substitution; Preferably, the amino acid sequence of the hRSV F protein before fusion includes at least one of S155C substitution, S190F substitution, V207L ​​substitution, S290C substitution, D486C substitution, and D489C substitution, and / or the P27 sequence of the hRSV F protein before fusion is replaced with a GS sequence; Preferably, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L ​​substitution, S290C substitution, D486C substitution, and D489C substitution, and the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74, and the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; Preferably, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L ​​substitution, S290C substitution, D486C substitution, D489C substitution, the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence as shown in Seq ID NO.74, and the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the hRSV F protein before fusion also includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, and K465Q substitution.

4. The immune composition according to claim 1 or 2, characterized in that The hRSV F protein before fusion includes an amino acid sequence in which at least one of the amino acids of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence or the 551-574 sequence is continuously or intermittently deleted.

5. The immune composition according to claim 1 or 2, characterized in that The amino acid sequences of the hRSV F proteins before fusion are shown in Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.68, Seq ID NO.70, Seq ID NO.72, Seq ID NO.76, and Seq ID NO.78; Preferably, the amino acid sequence of the hRSV F protein before fusion is shown in Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, and Seq ID NO.78; Preferably, the amino acid sequence of the hRSV F protein before fusion is shown in Seq ID NO.62, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, and Seq ID NO.

78.

6. The immune composition according to claim 5, characterized in that The multimerization element of the pre-fusion hRSV F protein can also be selected from the amino acid sequences shown in Seq ID NO.1-12 and Seq ID NO.14-15.

7. The immune composition according to claim 1 or 2, characterized in that The immune composition is a nucleic acid immune composition; the nucleic acid immune composition comprises a nucleic acid molecule; the nucleic acid molecule comprises a DNA molecule and / or an RNA molecule; preferably, the DNA molecule comprises a chain DNA molecule and / or a circular DNA molecule; preferably, the RNA molecule comprises an mRNA or a circular RNA; preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.63, Seq ID NO.65, Seq ID NO.67, Seq ID NO.69, Seq ID NO.71, Seq ID NO.73, Seq ID NO.77, Seq ID NO.79, and Seq ID NOs.84 to 103; Preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, and Seq ID NOs.84 to 103; Preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.92-103; Preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103; Preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.67; Preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.71; Preferably, the nucleotide sequence of the multimerization element in the open reading frame (ORF) can also be as shown in Seq ID NO.36-47 and Seq ID NO.

13.

8. The immune composition according to claim 1 or 2, characterized in that The immune composition comprises a delivery preparation; preferably, the delivery preparation comprises lipid nanoparticles or cationic liposomes.

9. The method for preparing the immune composition according to claim 7, characterized in that: The mRNA and a delivery formulation are mixed to form an immunological composition; the delivery formulation comprises lipid nanoparticles or cationic liposomes.

10. An isolated mRNA, characterized in that The coding region nucleic acid sequence of the mRNA encodes a pre-fusion hRSV F protein, and the amino acid sequence of the pre-fusion hRSV F protein includes a TM sequence and a multimerization element; preferably, the amino acid sequence of the multimerization element is as shown in Seq ID NO.1-12 and Seq ID NO.14-15; preferably, the amino acid sequence of the multimerization element is as shown in one of Seq ID NO.7 and Seq ID NO.12; Preferably, the mRNA further comprises: at least one of: a 5' end cap, a 5' UTR, a 3' UTR and a 3' end poly A tail; preferably, the 5' end cap is selected from ARCA, mCAP, dmCAP, tmCAP, m7G(5"")ppp(5"")(2""OMeA)pG, m7(3""OMeG)(5"")ppp(5"")(2""OMeA)pG, m7(3""OMeG)(5"")ppp(5"")(2""OMeG)pG, dmCAP or m7G(5"")ppp(5"")(2""OMeG)pG; Preferably, the length of the polyA tail at the 3' end is 50 to 200; preferably, the length of the polyA tail at the 3' end is 80 to 200; preferably, the length of the polyA tail at the 3' end is 80 to 120; preferably, the length of the polyA tail at the 3' end is 120; Preferably, the length of the 5'UTR is preferably 10 to 200 nucleotides, preferably 15 to 100 nucleotides; preferably, the 5'UTR nucleotide sequence is as shown in Seq ID NO.16-18; preferably, the 5'UTR nucleotide sequence is as shown in Seq ID NO.16; Preferably, the 3'UTR sequence is as shown in Seq ID NO.19 to 21; Preferably, the 3'UTR sequence is as shown in Seq ID NO.19; Preferably, one or more uridines in the mRNA are replaced with modified nucleosides; preferably, the modified nucleosides are pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) or 5-methyl-uridine (m5U)(m5U); preferably, the modified nucleosides are N1-methyl-pseudouridine (m1ψ).

11. An isolated DNA, characterized in that The DNA is obtained by reverse transcription of the mRNA nucleic acid isolated as claimed in claim 10, or the DNA is a sequence that can transcribe the mRNA isolated as claimed in claim 10.

12. A biological material, comprising any one of an expression cassette, a vector, an engineered bacterium or a cell line, wherein the biological material contains or expresses the mRNA isolated according to claim 10 or the DNA isolated according to claim 11.

Citation Information

Patent Citations

  • Medicine for expressing interleukin 12 aiming at tumors based on mRNA and preparation method thereof

    CN113509542A

  • Cyclic RNA compositions and methods

    CN116113419A

  • Recombinant human / bovine parainfluenza virus 3 (b / hpiv3) expressing a chimeric rsv / bpiv3 f protein and uses thereof

    CN107406835A

  • Conformationally stabilized RSV pre-fusion f proteins

    CN111405907A

  • Stabilized RSV F proteins and uses thereof

    CN111655715A